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Chapter 1
General introduction
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Cystic Fibrosis
Cystic Fibrosis (CF) is a severe, life-shortening genetic disease with a wide spectrum of 
clinical manifestations, affecting 70,000 patients in the EU and USA. The most prevalent 
clinical manifestation is structural lung disease. Structural lung disease is the main cause 
of morbidity in CF and accounts for 85% of the deaths in CF patients (1). Important for the 
pathogenesis of structural lung disease are genetic mutations on chromosome 7 encoding 
for the CF transmembrane conductance regulator (CFTR) (2-4). The most prevalent muta-
tion is the dF508 deletion, but nowadays over 1926 mutations of the CFTR gene have been 
described not all resulting in CF and accounting for different disease severities (5). The wild 
type CFTR protein resides in the membrane of epithelial cells, and regulates the airway 
surface liquid by ion flux through the chloride channels at the epithelial surface (2,4). Due 
to CFTR gene mutations a dysfunctional CFTR protein is produced. Dysfunctional CFTR 
results in reduced or absent chloride secretion and increased sodium absorption, lead-
ing to an increase in mucus viscosity and impaired mucociliary clearance (6). As a result 
there is poor clearance of inhaled microorganisms. Chronic endobronchial infection by 
these microorganisms provokes an exaggerated inflammatory response leading eventu-
ally to structural lung damage (7,8). Despite extensive research many questions related to 
the pathophysiology of CF lung disease remain unanswered (7). It is well recognized that 
genetic and environmental modifiers can alter outcome. Importantly, prognosis is nowa-
days still primarily determined by the severity of CF lung disease (7). Therefore, in order to 
improve prognosis, CF lung disease should be prevented.
CF lung disease
The lungs of a CF patient are thought to be normal at birth. However, structural lung 
damage can already be observed at the age of 10 weeks (9-15). The most prominent com-
ponents of CF lung disease are bronchiectasis and trapped air (16). Bronchiectasis is an 
irreversible dilatation of an airway, which develops over time as a consequence of chronic 
inflammation and infection leading to destruction of structural components of the bronchial 
wall. Using chest computed tomography (CT) it has been shown that 50 to 70% of children 
with CF develop bronchiectasis within the first 5 years of life (9,11,17). Trapped air on 
chest CT represents small airway disease. End-expiratory chest CT is the best modality to 
visualize the volume and distribution of trapped air (18). Two-thirds of the newly diagnosed 
infants with CF already have trapped air at the age of 1 year (9). It is therefore considered 
to be an important marker of early CF lung disease (9-11,16,19). Other important compo-
nents of CF lung disease are mucus plugging, airway wall thickening and consolidation or 
atelectasis (16). 
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Monitoring CF lung disease
In order to prevent structural changes in the lungs, early detection and good monitoring 
are important. To detect and monitor structural changes in the lungs, several diagnostic 
modalities are used in clinical practice and in clinical trials. These diagnostic modalities 
can be categorized into: imaging techniques to visualize lung structure and measures of 
the function of the lung, which can be measured by a wide array of lung function tests. 
The most important imaging techniques for monitoring CF lung disease are nowadays 
chest Computed Tomography (CT) and chest Magnetic Resonance Imaging (MRI). Another 
method to monitor CF lung disease is related to patient’s symptoms, which can be mea-
sured with the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Finally physical examination 
still plays an important role in the day to day monitoring of CF lung disease. 
Lung function tests
To measure the function of the lung, spirometry and in particular the forced expiratory vol-
ume in one second (FEV1), has been used as the primary outcome measure for both disease 
management and clinical trials (20-22). Although spirometry is widely used, it has several 
limitations. Firstly, FEV1 is a relatively insensitive outcome measure for detecting and moni-
toring early stages of CF lung (23). Considerable structural lung damage can be present 
even with a normal FEV1 (20). Secondly, spirometry requires active cooperation and can 
therefore only be reproducibly performed in most children of 6 years and older. Pre-school 
spirometry has been developed for children below the age of 6 years. In children aged 3 
to 5 years, spirometry is based on computer-incentive games. Success rates between 45-
75% have been reported (24-26). In children below 3 years of age infant pulmonary testing 
can be used but it requires sedation, is time consuming, and is technically difficult (27,28). 
A promising outcome measure in young children is the lung clearance index (LCI) derived 
from multiple breath washout techniques, which can be performed without sedation. The 
LCI has shown to be associated with structural lung disease, however it is not clear whether 
LCI is as sensitive as chest CT to monitor disease progression (19,22,29,30).
Chest imaging: CT and MRI
Chest CT is the most sensitive method to detect and monitor structural changes, like bron-
chiectasis and trapped air in the lungs (20,31-34). A disadvantage of CT is ionizing radiation 
(35). To minimize radiation exposure, low-radiation-dose CT scanning protocols have been 
developed. Furthermore, chest MRI has been suggested as a radiation free alternative for 
the diagnosis and monitoring of CF lung disease (36-39). The sensitivity of chest MRI to de-
tect morphological changes such as bronchiectasis and trapped air is considered to be in-
ferior to that of chest CT. This is especially true for early CF lung disease (36-39). However, 
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in the assessment of functional characteristics of the lung such as lung perfusion assessed 
by MRI or CT angiography and lung ventilation assessed by hyperpolarized helium MRI or 
Xenon CT, MRI is considered to be the established modality. To quantify changes in lung 
structure semi-quantitative scoring methods for chest CT and MRI have been developed 
and validated (40-43). In addition automated quantitative measurements of structural lung 
disease for chest CT are under development.
Quality of life measurements
To quantify a patient’s symptoms, the Cystic Fibrosis Questionnaire-Revised (CFQ-R) has 
been developed. The CFQ-R is a reliable and well-validated health-related quality of life 
measure, which meets the Food and Drug Administration (FDA) criteria for patient-report-
ed outcome measures. According to the FDA a patient-reported outcome measure is the 
most sensitive method to measure quality of life (44). 
For clinical management and clinical trials the CFQ-R has been translated and validated in 
multiple languages, including Dutch (44,45).  There are three age-specific versions of the 
CFQ-R: 1) the CFQ-R Child version for ages 6-13 years; 2) the CFQ-R Teen/Adult version 
for ages 14 years and older; and 3) the CFQ-R Parent version, for parents of the children 
aged 6-13 years. All versions consist of several domains (e.g. Physical functioning, Vitality, 
Health perceptions, Respiratory symptoms scale), but the CFQ-R Respiratory Symptoms 
scale (CFQ-R RSS) is the most commonly used domain as it is impacted most by CF lung 
disease (46-51). The scores within each domain are standardized into scores ranging from 0 
to 100, with higher scores indicating better health-related quality of life. Furthermore, the 
minimal important clinical difference for the CFQ-R RSS has been established, providing a 
systematic way to interpret changes in clinical status and to evaluate treatment response 
(44,52).
Validation of outcome measures
Currently, the most widely used outcome measure for CF lung disease is FEV1 derived 
from spirometry. FEV1 is well validated, however it is a relatively insensitive measure for 
diagnosing and monitoring CF lung disease. Therefore it has become less suitable over the 
last decades as a primary outcome in clinical trials, especially when studying early stages 
of CF lung disease (20-22). To detect and monitor CF lung disease in clinical practice and 
in clinical trials it is crucial to use sensitive, reproducible and feasible outcome measures.
Chest CT is a more direct and sensitive method than spirometry to study structural lung 
changes in CF lung disease, like bronchiectasis and trapped air. CT derived scores for 
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bronchiectasis and trapped air are relatively well validated as outcome measures in CF 
(9,16,20,23,31,40,53-60). Studies have shown that chest CT is 4-8 times more sensitive than 
FEV1 for detecting disease progression (20-22). Furthermore, CT derived bronchiectasis 
score is associated with pulmonary exacerbations (56,61), is high in end-stage lung disease 
(16), and is associated with mortality (16). The importance of CT derived trapped air score, 
as an outcome measure has been less well established than bronchiectasis. Nevertheless 
it is considered to be an important component of CF lung disease, since it is the earliest 
structural abnormality on CT, preceding the occurrence of bronchiectasis, and in end-stage 
disease it makes up to 80% of the total lung volume (9,10,16,19). 
Although extensive validation of chest CT related outcome measures has been performed, 
there are some important steps in the validation portfolio of chest CT missing. Firstly, the 
link between structural lung damage as established by CT and their impact on quality of 
life has not been established. 
Secondly, the relation between trapped air and pulmonary exacerbations has not been well 
established (62). Thirdly, risk factors for progression of structural lung damage on chest CT 
have not been well established. Fourthly, whether early reversible stages of bronchiectasis 
can be identified is not clear. 
For chest MRI, in contrast to chest CT, the validation process is at an early stage. Only few 
studies have validated MRI derived outcome measures for CF lung disease (36,38,39). Im-
portantly, MRI should be validated against established outcome measures of CF lung dis-
ease such as FEV1, pulmonary exacerbations and quality of life, measured with the CFQ-R. 
The CFQ-R is well validated and has been utilized successfully in both controlled trials and 
longitudinal studies (46-51). The CFQ-R RSS was used as an outcome measure in several 
clinical trials showing responsivity to inhaled tobramycin (49), dornase alfa (50), hyper-
tonic saline (51), and ivacaftor (47). It was used as primary outcome in a phase III study for 
FDA approval of aztreonam lysine for inhalation. In this study, a significant improvement 
in CFQ-R RSS was observed in the treated versus placebo group, with continued efficacy 
documented in an 18 month open-label follow up study (46,63). 
 Although a minimal clinical important difference has been established for the CFQ-R RSS, 
it is not clear how changes in respiratory symptoms measured with the CFQ-R RSS are re-
lated to the extent and progression of bronchiectasis and trapped air (52). 
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Aim of the study
In this thesis, 5 studies are presented. The aims of these studies were to further validate 
CT, MRI and the CFQ-R as outcome measures for the diagnosis and monitoring of CF lung 
disease.
To further validate chest CT as an outcome measure we:
•	 study the impact of bronchiectasis and trapped air on CT and pulmonary exacerba-
tions and quality of life  (Chapter 2).
•	 assess the associations between structural lung damage on CT and quality of life 
(Chapter 2 and 3).
•	 determine the risk factors for progression of structural lung damage on CT (Chapter 4).
•	 evaluate the development of bronchiectasis using consecutives CTs (Chapter 5).
To further validate chest MRI as an outcome measure we:
•	 study the relation between structural lung damage on MRI and FEV1, pulmonary exac-
erbations and quality of life (Chapter 6).
To further validate CFQ-R as an outcome measure we:
•	 assess if a change in respiratory symptoms reflects the extent of bronchiectasis and 
trapped air on CT (Chapter 2,3).
•	 assess if a change in respiratory symptoms reflects the extent of bronchiectasis and 
trapped air on MRI (Chapter 6).
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outline of this thesis
Chapter 1 Contains the introduction to the studies that are described in this thesis.
Chapter 2 Describes a cross-sectional study in which CT scores for bronchiectasis and 
trapped air were correlated with quality of life scores and with pulmonary 
exacerbations.  
Chapter 3 Describes a longitudinal study evaluating associations between changes in 
bronchiectasis, trapped air and patient-reported respiratory symptoms.
Chapter 4 Identifies predictors for bronchiectasis and trapped air severity over a 6 year 
follow up in children ages 6-13 years.
Chapter 5 Describes the development of bronchiectasis in CF on chest CT and identifies 
determinants for rapid progression of bronchiectasis.
Chapter 6 Describes the associations between MRI scores for bronchiectasis and trapped 
air and clinical markers of disease severity.
Chapter 7 Provides a general discussion on the results of the studies performed in this 
thesis.
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ABstRACt
Background. Cystic fibrosis (CF) is primarily characterized by bronchiectasis and trapped 
air on chest computed tomography (CT). The Cystic Fibrosis Questionnaire-Revised Respi-
ratory Symptoms scale (CFQ-R RSS) measures health-related quality of life. 
Objective. To validate bronchiectasis, trapped air and CFQ-R RSS as outcome measures, 
we investigated correlations and predictive values for pulmonary exacerbations.
Methods. CF patients (6-20 years) had a CT, CFQ-R RSS and 1 year follow-up. Bronchiec-
tasis and trapped air were scored using the CF-CT scoring system. Correlation coefficients 
and backward multivariate modeling were used to identify predictors of pulmonary exac-
erbations.
Results. 40 children and 32 adolescents were included. CF-CT bronchiectasis (r=-0.38, 
p<0.001) and CF-CT trapped air (r=-0.35, p=0.003) correlated with CFQ-R RSS. Pulmonary 
exacerbations were associated with: bronchiectasis (rate ratio (RR) 1.10, 95% Confidence 
Interval (CI95%) 1.02 to 1.19, p=0.009), trapped air (RR 1.02, CI95% 1.00 to 1.05, p=0.034), 
and CFQ-R RSS (RR 0.95, CI95% 0.91 to 0.98, p=0.002). The CFQ-R RSS was an independent 
predictor of pulmonary exacerbations (RR 0.96, CI95% 0.94 to 0.97, p<0.001).
Conclusion. Bronchiectasis, trapped air and CFQ-R RSS were associated with pulmonary 
exacerbations. The CFQ-R RSS was an independent predictor. This study further validated 
bronchiectasis, trapped air and CFQ-R RSS as outcome measures.
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IntRoDUCtIon
Cystic Fibrosis (CF) is a severe, life-shortening genetic disease affecting 70,000 patients in 
the EU and USA. The most prominent components of CF lung disease are bronchiectasis and 
trapped air. Bronchiectasis reflects irreversible widening of the airways and trapped air as-
sesses small airway disease. Both bronchiectasis and trapped air typically begin in early child-
hood and progress slowly throughout life, eventually leading to end-stage lung disease (1,2).
Bronchiectasis and trapped air are important indicators of prognosis (3-5). Therefore accu-
rate and sensitive monitoring of these indicators is needed for optimal clinical management 
and as potential outcome measures in clinical trials. To date, forced expiratory volume in 
one second (FEV1), derived from pulmonary function tests (PFT), has been the central out-
come measure for disease management and clinical trials. However, FEV1 is a relatively 
insensitive measure for detecting and monitoring disease progression (6). Bronchiectasis, 
assessed with chest computed tomography (CF-CT bronchiectasis score), is more sensitive 
and accurate than chest radiograph (6). Literature suggests that the CF-CT bronchiectasis 
score is a valuable outcome measure since it is associated with pulmonary exacerbations 
(7,8), is an important component of end-stage lung disease (9), and is associated with 
mortality (9). It is not known whether the presence of bronchiectasis correlates with stan-
dardized, patient-reported outcome measures (10). In adults with chronic obstructive pul-
monary disease, bronchiectasis is associated with reduced health-related quality of life, as 
measured by the symptoms scale of the St George Quality of Life Questionnaire (11). We 
hypothesized that a similar association may exist for bronchiectasis in CF. 
The importance of trapped air as an outcome is less well-established than bronchiectasis. 
The volume and distribution of trapped air can be visualized well on end-expiratory chest 
CT (12). Trapped air is observed in approximately two-thirds of newly diagnosed infants, 
it is also an important component of end-stage lung disease  (1,4,9). Hence, trapped air 
is considered a potential marker of early CF lung disease  (2-4,9). To date, as an outcome 
measure for clinical management and trials, trapped air has not yet been validated against 
other clinical markers of disease severity, such as pulmonary exacerbations and patient-
reported respiratory symptoms on a health-related quality of life measure. 
Standardized, well-validated measures of health-related quality of life in CF, such as the 
disease-specific Cystic Fibrosis Questionnaire-Revised (CFQ-R) have been developed (13). 
The CFQ-R consists of several domains (e.g. Physical Functioning, Vitality, Health Percep-
tions, Respiratory Symptoms Scale (CFQ-RSS)). The CFQ-R Physical Functioning scale, 
CFQ-R Vitality scale, CFQ-R Health Perceptions and CFQ-R RSS have been shown to corre-
late to FEV1 (14). The CFQ-R RSS has been utilized successfully in both controlled trials and 
longitudinal studies (15-20). The CFQ-R RSS was used as an outcome measure in several 
clinical trials showing responsivity to inhaled tobramycin (18), dornase alfa (19), hypertonic 
saline (20), and ivacaftor (16). CFQ-R RSS was used as primary outcome in a phase III study 
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for Food and Drug administration (FDA) approval of aztreonam lysine for inhalation. A sig-
nificant improvement in CFQ-R RSS was found in the treated versus placebo group, with 
continued efficacy documented in an 18 month open-label follow up study  (15,21). 
Although a minimal important difference has been established for the CFQ-R RSS, it is 
not clear what change in respiratory symptoms reflects the extent of bronchiectasis and 
trapped air (22).
The objectives of this study were to further validate bronchiectasis and trapped air as out-
come measures by correlating them with CFQ-R RSS and pulmonary exacerbations. Fur-
thermore we aimed to validate bronchiectasis, trapped air, and CFQ-R RSS by investigating 
their predictive value for pulmonary exacerbations in the following year.
MetHoDs 
Study population
Patients (aged 6-20 years) were diagnosed as having CF by a positive sweat test and/or 
genotyping for known CF mutations. We included clinically stable children and adolescents 
with CF, monitored at the Erasmus MC-CF Center Rotterdam, who had a CFQ-R and CT 
performed on the same day, at the annual check-up and at 1 year follow-up. If CT and the 
CFQ-R were not completed on the same day, a maximal time difference of 3 months was 
considered acceptable (n=1). Patients in need of intravenous antibiotics for respiratory 
signs or symptoms at the time of the annual examination were considered unstable and 
excluded. This retrospective cohort study was approved by the Institutional Review Board 
of the Erasmus MC-CF Center Rotterdam (MEC-2011-250). 
Chest-CT evaluation of bronchiectasis and trapped air
All volumetric CTs were acquired using a 6-slice multi-detector CT scanner (Siemens Medi-
cal Solutions, Germany). Each CT consisted of a volumetric inspiratory and expiratory ac-
quisition. Instructions for voluntary breath holds were given before scanning. kV tube volt-
ages of 80 (patients < 35 kg) or 110 (patients > 35 kg) were used with a 0.6-sec rotation 
time. Scanning was done from apex to base at 1.5 pitch and 6x2 mm collimation. Images 
were reconstructed with a 3.0 mm slice thickness, 1.2 mm increment and kernel B60s. For 
the inspiratory protocol a modulating current was used (Siemens) with a reference tube 
current-time product of 20 mAs, for optimal image quality. For expiratory CTs a tube cur-
rent fixed at 25 mA with an effective tube current-time product of 10 mAs (the typical value 
for a 5-year-old child) was used. This produced a lower radiation dose than the inspiratory 
protocol with sufficient image quality. Total radiation dose was in the order of 1 mSv. 
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All CTs were scored using the CF-CT scoring system, a modified version of Brody II scoring, 
evaluating the 5 lung lobes and the lingula as a sixth lobe for severity, extent of central and 
peripheral bronchiectasis, airway wall thickening, central and peripheral mucus plugging, 
opacities (atelectasis, consolidation, ground glass pattern) and cysts and bullae on inspira-
tory CTs and the pattern and extent of trapped air on expiratory CTs  (7,23). The maximal 
possible composite CT score is 207 points. For statistical analysis, composite and compo-
nent CT scores were expressed as a percentage of the maximum possible score (0-100). All 
scans were de-identified, using Myrian Ò intrasense France, and scored in random order by 
an observer blinded to clinical background (7). 
To test the intra-observer agreement, observer 1 rescored 25 random scans after one 
month. A second observer scored 25 random scans to assure a good inter-observer agree-
ment. Both observers were trained in CF-CT scoring and began scoring the study CTs after 
establishing good intra- and inter-observer agreement.
Table 1. Baseline characteristics of the study cohort. 
Characteristic Total group Children Adolescents
Number of patients 72 40 32
Gender (Males) 35 (48.6) 20 (50) 15 (46.9)
Age, year 13.4 (6-20) 11.5 (6-14) 16.5 (14-20)
FEV1, % predicted 83.4 (22-110) 85.7 (31-110) 75.9 (22-110)
FVC, % predicted 91.9 (32-119) 97.9 (53-119) 85.9 (32-112)
FEF 75 % predicted 48.5 (6-95) 48 (7-95) 49.2 (6-92)
Positive Pseudomonas aeruginosa culture* 26 (36) 10 (25) 16 (50)
Chronic infection with Pseudomonas aeruginosa** 19 (26) 5 (13) 14 (44)
CF-CT total score, % 7.8 (0-33) 5.2 (0-20) 11.8 (0-33)
Bronchiectasis score, % 0.0 (0-26) 0 (0-19) 2.6 (0-26)
Airway wall thickening score, % 8.3 (0-37) 4.9 (0-33) 14.8 (0-37)
Mucus plugging score, % 8.3 (0-50) 5.6 (0-50) 16.7 (0-42)
Opacities, % 5.6 (0-19) 4.6 (0-13) 7.4 (0-19)
Trapped air, % 36.7 (0-97) 33.3 (0-70) 43.3 (7-97)
 
Data are presented as no. (%) or median (range), unless otherwise indicated. FEF75 = forced expiratory 
flow	at	75%	of	vital	capacity.
* includes all positive Pseudomonas aeruginosa cultures positive in the year previous to the CT and CFQ-
R.
**	defined	as	≥	3	consecutive	positive	respiratory	cultures	for	Pseudomonas	aeruginosa.
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CFQ-R
Three age-appropriate versions of the Dutch CFQ-R were administered, using a multi-infor-
mant approach (Table 2): 1) the CFQ-R Child Version (ages 6-13; 35 items covering 8 do-
mains); 2) CFQ-R Parent Version (caregivers of children 6-13; 43 items covering 11 domains) 
3) CFQ-R Teen/Adult Version (ages > 14 years; 47 items covering 12 domains) (13). In addi-
tion to analyzing the CFQ-R RSS, we analyzed 3 health-related secondary domains; CFQ-R 
Physical Functioning, CFQ-R Vitality and CFQ-R Health Perceptions scale. Unfortunately, the 
CFQ-R Vitality and CFQ-R Health Perceptions do not exist for younger children (CFQ-R Child 
Version).
All scale scores were standardized on a 0-100 scale, with higher scores indicating better 
health-related quality of life (13).
PFT and pulmonary exacerbations
PFT results (diagnostic system: Jaeger AG) were expressed as percentages of predictive 
values, according to Stanjonevic for Forced vital capacity (FVC) and FEV1, and Zapletal for 
the forced expiratory flow at 75% (FEF75)  (24,25).
Because there is no consensus on the definition of pulmonary exacerbations, they were 
conservatively defined as: episodes of treatment with IV antibiotics for pulmonary indica-
tions in the year following administration of CT and CFQ-R  (7,8). Pseudomonas aeruginosa 
positivity	as	defined	as:	presence	of	≥	1	and	<3	positive	respiratory	cultures	 in	 the	year	
previous to the CT scan. Chronic colonization with Pseudomonas aeruginosa as defined as: 
≥	3	consecutive	positive	respiratory	cultures.
Table 2. Selected CFQ-R scores for children, their parents and adolescents.
Selected domain of 
the CFQ-R
Children
(6-13 years)
Adolescents
(≥14 years)
CFQ-R Child version 
n=40
CFQ-R Parent version 
n=37
CFQ-R Teen/Adult version
n=32
CFQ-R RSS 83 (50-100) 89 (50-100) 77 (11-100)
Physical Functioning 83 (39-100) 93 (52-100) 90 (38-100)
Vitality - 73 (47-93) 67 (25-100)
Health Perceptions - 78 (22-100) 67 (22-100)
CFQ-R scale scores for the different versions of the CFQ-R. CFQ-R RSS was the primary target.  Physi-
cal Functioning, Vitality and Health Perceptions were secondary domains correlating with FEV1. For each 
domain, a score between 0-100 is calculated. Higher scores indicate better health-related quality of life. 
Data are presented as median (range). 
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Statistical analysis 
Inter- and intra-observer agreement of CF-CT scores were calculated using intraclass cor-
relation	coefficients	(ICC)	(ICC	0.40	-	0.60=	moderate,	0.60	-	0.80	=	good,	and	≥	0.80=	very	
good agreement). In case of low or moderate agreement between the observers Bland-
Altman plots were calculated and for visualizing whether one over- or underestimated the 
CT scores on the different indices (26). Spearman’s correlation coefficients were used to 
correlate CF-CT bronchiectasis and CF-CT trapped air scores with CFQ-R RSS, CFQ-R 
Physical Functioning, CFQ-R Vitality and CFQ-R Health Perceptions scale scores. Negative 
binomial regression models were used to investigate the association between CF-CT bron-
chiectasis, CF-CT trapped air and CFQ-R RSS and the number of pulmonary exacerbations 
in the subsequent year. A multivariate model was evaluated (backward, stepwise approach) 
to identify independent predictors of pulmonary exacerbations in the subsequent year. In 
order to reach sufficient power the univariate and multivariate regression analyses were 
performed on the complete study population (n=72). Analyses were repeated using the 
CFQ-R Child Version and CFQ-R Parent Version in children aged 6-13 years. In our final 
model the CFQ-R Child Version was used, because it is better to use the patients own 
report on his/her symptoms as recommended by the Food and drug administration (FDA) 
and European Medicines Agency (EMA). To interpret our results in clinical terms, we used 
a logistic model.
Statistical analyses were performed using SAS version 9.2. Results are displayed as median 
(range) unless otherwise defined. Two tailed-testing was performed. P-values < 0.05 were 
considered to be significant.
ResULts
Study population
Seventy two patients (40 children, 32 adolescents) had 72 CTs and PFTs completed. Base-
line characteristics are shown in Table 1. A total of 109 CFQ-Rs were collected: 40 CFQ-R 
Child, 37 CFQ-R Parent, and 32 CFQ-R Teen/Adult measures. Three parents did not return 
the CFQ-R (see Table 2). ICCs for within-observer agreement ranged from 0.68 (CF-CT 
trapped air score) to 0.98 (CF-CT bronchiectasis score), whereas between-observer agree-
ment ranged from 0.50 (CF-CT trapped air score) to 0.91 (CF-CT total score).
Correlations between CT and CFQ-R (see Table 3)
In children the CF-CT Airway wall thickening (p<0.001), mucus plugging (p<0.001) and 
opacities (p=0.007) were significantly correlated with the CFQ-R RSS. Similarly, CF-CT air-
way wall thickening and mucus plugging were significantly correlated with the CFQ-R RSS 
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scores in the parent, but also the CF-CT bronchiectasis score (p=0.033). Similar associa-
tions were found among adolescents: CF-CT bronchiectasis score (p=0.007), airway wall 
thickening (p=0.005), mucus plugging (p=0.004), and opacities (p=0.004) all significantly 
correlated with the CFQ-R RSS scores.
No significant correlations were found between the CF-CT scores and the Physical Func-
tioning scale in children, whereas in adolescents all of the CF-CT scores correlated. 
In the other health-related secondary domains (Vitality and Health Perceptions), only CFQ-
R Health Perceptions in adolescents was significantly associated with CF-CT airway wall 
thickening (p=0.038), and CF-CT mucus plugging (p=0.041). 
Across ages (n=72), CF-CT bronchiectasis scores were significantly correlated with CFQ-
R RSS (r=-0.38, p<0.01), with more structural changes associated with worse respiratory 
symptoms (Figure 1). This relationship was also present between CF-CT trapped air scores 
and CFQ-R RSS (r=-0.35, p<0.01) (Figure 2). 
Figure 1. Correlation between CFQ-R RSS and CF-CT bronchiectasis score across ages (n=72) **  
p < 0.01.
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Associations between CT, CFQ-R RSS and pulmonary 
exacerbations in the following year (Table 4)
CF-CT bronchiectasis scores were significantly associated with the number of pulmonary 
exacerbations in the following year, rate ratio of 1.10 (95% Confidence Interval (CI95%) 1.02 
to 1.19, p=0.009). This indicates that the expected number of pulmonary exacerbations 
increased 10% in the following year (CI95% 2.4 to 19%) for each 1 point increase in a pa-
tient’s CF-CT bronchiectasis score. The rate ratio for CF-CT trapped air on pulmonary ex-
acerbations in the following year was smaller, but also significant, 1.02 (CI95% 1.00 to 1.05, 
p=0.034). CFQ-R RSS were associated with pulmonary exacerbations in the following year, 
rate ratio of 0.95 (CI95% 0.91 to 0.98, p=0.002). Thus, the expected number of pulmonary 
exacerbations decreased 5% for each 1 point increase in CFQ-R RSS scores.
Figure 2. Correlation between CFQ-R RSS and CF-CT trapped air score across ages (n=72) ** p < 0.01.
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Prediction model for pulmonary exacerbations
Seventy-two patients had complete longitudinal data for the multivariate prediction model. 
Due to the relatively small sample size, a limited number of predictors were tested: gen-
der, age, CF-CT bronchiectasis score, CF-CT trapped air score, CFQ-R RSS and positive 
culture for Pseudomonas aeruginosa in the year before the CT. In the final model, sig-
nificant predictors of subsequent pulmonary exacerbations were: age (p=0.001), CFQ-R 
RSS (p<0.001), and positive cultures for Pseudomonas aeruginosa (p=0.008) (Table 4). A 
decrease of one point in CFQ-R RSS scores predicted a 4.7% (CI95% 3.0 to 6.3 %) increase of 
pulmonary exacerbations in the following year. Quittner et al. showed that a 4-point reduc-
tion in CFQ-R RSS scores was clinically meaningful (22). According to the logistic model 
used in our study, this would equate to a 20% (4.74) increase in the number of pulmonary 
exacerbations in the following year. To determine whether CFQ-R scores were merely a 
reflection of the number of pulmonary exacerbations in the previous year, we performed a 
sensitivity analysis adding the number of pulmonary exacerbations in the previous year to 
the multivariate model. Interestingly, CFQ-R RSS scores continued to add predictive value 
for number of pulmonary exacerbations in the following year (2.6% decrease per point in 
CFQ-R, CI95% 0.4 to 4.8, p=0.014). CF-CT bronchiectasis and trapped air did not remain sig-
nificant in the multivariate model. No meaningful differences were present when the analy-
sis were performed, using the CFQ-R Parent Version in place of the CFQ-R Child Version. 
Table 4. Univariate and multivariate associations with pulmonary exacerbations in the following year. 
Predictor
Univariate associations Multivariate prediction model*
Rate 
Ratio† CI95% P-value
Rate 
Ratio† CI95% P-value
CF-CT bronchiectasis score 1.10 1.02-1.19 0.009 ns
CF-CT trapped air score 1.02 1.00-1.05 0.034 ns
CFQ-R RSS 0.95 0.91-0.98 0.002 0.96 0.94-0.97 <0.001
Positive culture 
Pseudomonas aeruginosa ‡
1.98 1.22-3.23 0.006 1.72 1.10-2.69 0.008
Age (years) 1.21 1.02-1.44 0.030 1.52 1.00-2.30 0.001
Gender 1.03 0.38-2.80 0.951 ns
N=72.	In	young	children	(6-13	years)	the	CFQ-R	Child	Version	was	used.	*:	Only	variables	significant	at	
p=0.05 level in multivariable model are included. †: Rate Ratio for scores calculated per point increase in 
score.	‡:		defined	as	≥	1	positive	respiratory	cultures	for	Pseudomonas	aeruginosa	in	the	past	12	months.
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DIsCUssIon
This is the first study to investigate the relationship between bronchiectasis and trapped 
air, assessed by chest CT and CFQ-R RSS scores. The most important finding was that more 
severe bronchiectasis was significantly associated with worsening respiratory symptoms. 
Bronchiectasis, trapped air and CFQ-R RSS were all significantly associated with pulmonary 
exacerbations in the following year.
The importance of bronchiectasis in CF lung disease has been well established  (1,3-5,7-9), 
however the impact of bronchiectasis on patient-reported outcome measures in CF had not 
previously been examined (10). Our finding that bronchiectasis and CFQ-R RSS are nega-
tively associated supports the validity of bronchiectasis as a clinically relevant outcome 
measure. Previous studies have shown that bronchiectasis was associated with pulmonary 
exacerbations in the following two years (7,8), while our data showed a similar association 
over a 1 year time period. Unfortunately, in our multivariate model, CF-CT bronchiectasis 
did not remain a significant predictor for pulmonary exacerbations, probably because we 
have a patient population with very mild CF, reflected by a median bronchiectasis score of 
0.00. 
Although trapped air has been less well validated as an outcome measure, we found a 
significant, independent correlation between trapped air and CFQ-R RSS. Although the 
associations between CF-CT trapped air scores and both CFQ-R RSS and pulmonary exac-
erbations were significant, they were not as strong as the associations with bronchiectasis. 
This may be because trapped air has less impact on patient functioning than bronchiectasis 
and can be reversible to some extent  (1,2). A recent study showed that patients with severe 
advanced lung disease, such as bronchiectasis, had a higher mortality risk compared to 
patients who predominantly had trapped air (9). Our results suggested that trapped air can 
also be considered as a valuable CT-related surrogate outcome measure in CF. 
Interestingly, we also found significant associations in other CT indices: CF-CT airway wall 
thickening, mucus plugging, and opacities were significantly associated with the CFQ-R 
RSS in children and adolescents. Airway wall thickening and mucus plugging are consid-
ered to be early indicators of developing disease, in contrast to bronchiectasis, which is 
considered to be a last stage of structural damage in the larger airways. Therefore, it is not 
surprising that these early indicators, and not bronchiectasis, were significantly associated 
with the CFQ-R RSS in the younger age group. Note that this was a young population with 
very mild CF lung disease. This further validates the CFQ-R RSS as a sensitive measure of 
structural lung damage in the early stages of CF lung disease. 
We found that the lower the CFQ-R RSS score, the higher the risk for pulmonary exacerba-
tions, irrespective of other predictors. This innovative result is consistent with the research 
of Britto et al. (27). They concluded that pulmonary exacerbations have a profound, nega-
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tive impact on health-related quality of life in CF-children, using a generic instrument (Child 
Health Questionnaire). Furthermore, our data suggested that the CFQ-R RSS is sensitive 
to early, minor respiratory symptoms preceding pulmonary exacerbations. Therefore the 
CFQ-R RSS may allow earlier detection of disease progression.
In our multivariate model, after including CFQ-R RSS, CT had no added value to predict 
the frequency of pulmonary exacerbations. It is important to realize that the CFQ-RSS and 
CT provide different information. The CFQ-R RSS focuses exclusively on the frequency and 
severity of respiratory symptoms, whereas CT provides critical information about structural 
lung changes like the extent of bronchiectasis and trapped air. CT also provides informa-
tion about airway wall thickening and mucus plugging, which can be considered as early 
leading indicators of developing disease. Consequently, aggressive treatment to prevent 
structural lung damage should be considered if either indicator is present on CT. Therefore, 
both CT and CFQ-R RSS are considered important outcome measures.
Limitations
This was a retrospective study. Therefore, we selected a robust, conservative definition of 
pulmonary exacerbations that were unlikely to be missed  (7,8,28,29). Data were collected 
from a single center, which may reduce the generalizability of the results. Furthermore, we 
used an age-range of 6 to 20 years; whether similar correlations exist in infant or adult CF 
populations requires further study. Considering the progressive nature of CF, we would 
expect a higher rate of pulmonary exacerbations in adults and thus, stronger associations.
In conclusion, we showed that in children with CF, more severe bronchiectasis and trapped 
air were associated with worse CFQ-R RSS scores. Bronchiectasis, trapped air and the CFQ-
R RSS were significantly associated with pulmonary exacerbations in the following year. Our 
findings validate the importance of CT measures of bronchiectasis and trapped air and the 
CFQ-R RSS as clinically relevant outcome measures for CF.
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ABstRACt
Background. Cystic fibrosis (CF) lung disease is characterized by bronchiectasis and 
trapped air on chest Computed Tomography (CT). 
Objective. We aim to validate bronchiectasis and trapped air as outcome measures by 
evaluating associations between changes in bronchiectasis, trapped air and patient-report-
ed respiratory symptoms.
Methods. A longitudinal cohort study has been conducted. CF patients (aged 6-19 years) 
who had two routine CTs and completed twice a Cystic Fibrosis Questionnaire-Revised 
within 2 years (referred to as T1 and T2), in the period of July 2007 to January 2012 were 
included. Bronchiectasis and trapped air were scored using the CF-CT scoring system. Cor-
relation coefficients and student’s paired t-tests were performed. 
Results. In total 40 patients were included with a median age at T1 of 12.6 years (range 
6-17 years), and at T2 14.5 years (range 8-19 years). At T1, bronchiectasis (r=-0.49, p<0.01) 
and trapped air (r=-0.34, p=0.04) correlated with CFQ-R Respiratory Symptoms Scores 
(CFQ-R RSS). At T2 similar correlations were found with the CFQ-R RSS. Over two years, 
there was significant progression in bronchiectasis (p=0.03) and trapped air (p=0.03), but 
not in CFQ-R RSS. Changes in bronchiectasis and trapped air were not associated with 
changes in CFQ-R RSS.
Conclusion. Our results indicate that bronchiectasis and trapped are sensitive outcome 
measures in CF lung disease, showing a significant association with CFQ-R RSS at two-time 
points. However, progression of bronchiectasis and trapped air over two year does not 
necessarily correlate to changes in quality of life.
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IntRoDUCtIon 
Cystic Fibrosis (CF) is a severe genetic disease affecting approximately 70,000 patients in 
Europe and the United States. Prognosis is primarily determined by the severity of lung dis-
ease. To improve treatment and prognosis, it is critical to conduct clinical trials using sen-
sitive, reproducible and feasible outcome measures (1,2). Many outcome measures have 
been evaluated in prior studies, leading to the identification of new endpoints. 
There are currently two endpoints considered to be measures of clinical status: 1) assess-
ment of pulmonary exacerbations, and 2) standardized questionnaires assessing respira-
tory symptoms, e.g. the Cystic Fibrosis Questionnaire-Revised Respiratory Symptoms scale 
(CFQ-R RSS). Other endpoints, such as bronchoalveolar lavage, markers of inflammation, 
spirometry, and imaging, are considered surrogate outcomes (1,2).
Currently, the most widely used surrogate outcome measure is Forced Expiratory Volume in 
one second (FEV1) derived from spirometry. However, FEV1 is a relatively insensitive meas-
ure for monitoring early CF lung disease (3-5). Studies have shown that chest Computed 
Tomography (CT) is 4-8 times more sensitive than FEV1 for detecting disease progression 
and therefore, a potential promising outcome measure (3). 
Given that progression of CF lung disease is primarily characterized by the development of 
bronchiectasis and trapped air, chest CT may offer advantages over other outcome mea-
sures. Bronchiectasis is a bronchial dilatation that begins early in life (6-8) and has been 
validated against other clinically meaningful outcomes. It correlates with mortality (9), is an 
important component of end stage lung disease (9), is strongly associated with pulmonary 
exacerbations (10-12), and correlates cross-sectionally to patient-reported outcomes (12).
Trapped air represents small airways disease. The volume and distribution of trapped air 
can be visualized on end-expiratory chest CT (13), but it is not as well-validated as an out-
come measure as bronchiectasis. Trapped air is the earliest structural abnormality on CT, 
preceding the occurrence of bronchiectasis (7,8,14). In end-stage disease, it is present in 
up to 40% of the total lung volume (9), and correlates with health-related quality of life (12). 
Bronchiectasis and trapped air are promising outcome measures, however further valida-
tion is needed.
The Cystic Fibrosis Questionnaire-Revised (CFQ-R), is a reliable and well validated health-
related quality of life measure that meets the FDA criteria for patient-reported outcome 
development and has been translated and validated in Dutch and other languages (15,16). 
The CFQ-R consists of several domains, some of which have been significantly associated 
with FEV1 (17); Respiratory Symptoms, Physical Functioning, Vitality, and Health Percep-
tions. Sawicki et al. showed that the CFQ-R RSS was sensitive to changes in respiratory 
symptoms over a 9-15 month study period (18), an independent predictor of pulmonary 
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exacerbations (12) and responsive to the effect of different kind of medications: inhaled 
tobramycin (19), dornase alfa (20), hypertonic saline (21), and ivacaftor (22). Less is known 
about the extent to which patient-reported respiratory symptoms reflect the progression 
of bronchiectasis and trapped air over longer time periods. For example, the CFQ-R has a 
two-week recall window whereas changes on a CT scan may be detectable over a longer 
time scale. 
Contributing to the validation of bronchiectasis and trapped air as new outcome meas-
ures, we evaluated the associations between bronchiectasis, trapped air, and CFQ-R scores 
cross-sectionally at two time periods (T1 and T2) and longitudinally over two years. We hy-
pothesized that progression of bronchiectasis and trapped air would be associated with a 
worsening of CFQ-R RSS scores over a two-year time period.
MAteRIALs AnD MetHoDs 
Study population
This longitudinal cohort study used clinical data from the annual evaluation of all children 
and adolescents with CF, treated in the Erasmus MC-CF Center (Rotterdam, the Nether-
lands) from July 2007 to January 2012, who completed a CT and CFQ-R twice (performed 
on the same day as part of their annual examination) and gave their consent to use their 
data. The included children and adolescents (aged 6-17 years) were clinically stable and 
diagnosed with CF by a positive sweat test and/or genotyping for known CF mutations. 
According to the routine annual examination of the Erasmus MC-CF center every child with 
CF completes a CFQ-R. A routine chest CT is performed biennially. Therefore the time be-
tween two CTs is approximately two years. T1 defines completion of the first CT and CFQ-R. 
T2 defines their completion at the second time point. Children and adolescents receiving 
intravenous antibiotics for respiratory symptoms at their annual examination were consid-
ered unstable and were therefore excluded. This study was approved by the Institutional 
Review Board of the Erasmus MC-CF Center (MEC-2011-460).
Chest CT evaluation and spirometry
All volumetric CTs were acquired using a 6-slice multi-detector CT scanner (Siemens Medi-
cal Solutions, Germany). Each CT consisted of a volumetric inspiratory and expiratory ac-
quisition. If the CT was not spirometry controlled, instructions for breath holds were given 
before scanning. The total radiation dose was approximately 1 mSv (on-line supplement).
All CTs were scored using the CF-CT scoring system, evaluating the 5 lung lobes and the 
lingula for our primary outcomes: severity, extent of central and peripheral bronchiectasis 
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(CF-CT bronchiectasis score), on inspiratory CTs, and the pattern and extent of trapped 
air (CF-CT trapped air score) on expiratory CTs (10,23). Other components of the CF-CT 
scoring system that were evaluated are the severity and extent of airway wall thickening, 
central and peripheral mucus plugging, opacities (atelectasis, consolidation, ground glass 
pattern), cysts and bullae.
For statistical analysis, the component CT scores (expressed as a percentage of the maxi-
mum possible score (0-100%)) of one observer were used. All scans were anonomyzed, 
using MyrianÒ (intrasense Montpelier, France), and scored in random order by observer 
1 blinded to clinical background (10). To assess intra-observer agreement, observer 1 re-
scored 25 scans after one month. A second random set of 25 scans was selected for ob-
server 2 to evaluate inter-observer agreement (9,10,24). Both observers were trained in 
CF-CT scoring. 
Spirometry was performed using a diagnostic system (Jaeger AG, Germany). Spirometry 
results (FEV1, FVC) were expressed as percentages of predictive values, according Stano-
jevic (25).
CFQ-R
The CFQ-R has different versions based on age: 1) the CFQ-R Child Version for ages 6-13 
years; 2) the CFQ-R Teen/Adult Version for ages 14 years and older, and 3) the CFQ-R Par-
ent Version, completed by parents of the children aged 6-13 years. We did not include the 
CFQ-R Parent scores in our analyses, because it is better to use the patient’s own report, 
according to both the FDA and European Medicines Agency (16). 
Several domains of the CFQ-R have been shown to correlate with FEV1 (17): Respiratory 
Symptoms Scale, Physical Functioning scale, Vitality scale, and Health Perceptions. CFQ-
R Vitality and Health Perceptions only appear in the Teen/Adult Version and given our 
sample size they were excluded from analysis. Our primary goal was to evaluate the CFQ-R 
RSS because it most directly reflects lung disease. Responses to items on each scale were 
standardized into scores ranging from 0 to 100, with higher scores indicating better health-
related quality of life. 
Statistical analysis
Inter- and intra-observer agreement of component CF-CT scores were calculated using in-
traclass correlation coefficients (ICC). Although no universally accepted standards are avail-
able for what constitutes good reliability, ICC values between 0.4 and 0.6, 0.6 and 0.8, and 
≥	0.8	are	considered	to	represent	moderate,	good	and	very	good	agreement.	According	to	
C
ha
p
te
r 3
44
Cohen’s criteria (1988) associations between 0.10 and 0.29 are considered weak, between 
0.30 and 0.49 intermediate and above 0.50 are considered strong associations. Systematic 
errors in component scores were evaluated using Bland-Altman plots, expressing the dif-
ferences between two observers as a function of their mean (26). 
Spearman’s correlation coefficients were used to correlate CF-CT bronchiectasis, trapped 
air, airway wall thickening, mucus plugging and opacities scores with CFQ-R RSS and Physi-
cal Functioning at T1 and T2. Student’s paired t-tests were used to determine whether there 
were significant changes over time in: CF-CT scores, FEV1, CFQ-R RSS, and Physical Func-
tioning. Changes in scores were calculated by taking the difference between the values 
at T2 and T1. Statistical analyses were performed using SPSS version 20.0 for windows. 
Continuous variables are displayed as medians (ranges). P-values less than 0.05 (two tailed) 
were considered statistically significant.
ResULts
Study population
Forty patients (Figure 1) completed the CT and CFQ-R protocol twice (T1: 29 children and 
11 adolescents). The median time interval between T1 and T2 was 2.0 years (range 0.9-4.0). 
In 4 of the included patients the time interval was less than 1.5 years and 1 patient had a 
four-year time interval between CTs. Baseline Characteristics of this cohort are shown in 
Table 1. 
At T1 we collected: 29 CFQ-R 
Child measures and 11 CFQ-
Rs Teen/Adult measures (Ta-
ble 2). At T2, 12 children had 
reached 14 years of age and 
therefore switched from the 
Child to the Teen/Adult Ver-
sion. At T2 we collected: 17 
CFQ-R Child measures and 
23 Teen/Adult measures. The 
CFQ-R scale scores at T1 and 
T2 are shown in Table 2. 
The ICC’s for intra-observer agreement for bronchiectasis and trapped air were respectively 
0.86 and 0.75, ranging from 0.72 (CF-CT opacities) to 0.86 (CF-CT bronchiectasis). Inter-
observer agreement for bronchiectasis and trapped air were respectively 0.89 and 0.69, 
ranging from 0.69 (CF-CT trapped air) to 0.95 (CF-CT mucus plugging).
Figure 1. Flowchart.
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Characteristic T1 T2 p-value Mean 
difference 
(CI95%)
Number of patients 40  40
Gender (Males) 19 47.5
Age, year 12.6 (6;17) 14.5 (8;19) <0.01** -1.9 (-2.1;-1.7)
Children 29 72.5 17 42.5
Adolescents 11 27.5 23 57.5
SES#
Low 6 16.7
Average 13 36.1
High 12 33.3
Scientific 5 13.9
Genetics
Homozygous dF508 25 62.5
Heterozygous dF508 13 32.5
Heterozygous other mutation 2 5.0
Presence of co-morbidities
Pancreatic insufficient 35 87.5
CFRD 3 7.5
Asthma 2 5.0
ABPA 1 2.5
Chronic colonization Pa 5 12.5
BMI 17.1 (13;31) 18.7 (13;30) <0.01** -1.0 (-1.5;-0.5)
FEV1, % predicted (n=37) 82.4 (31;114) 84.0 (37;117) 0.14  -6.5 (-15.2;2.3)
FVC, % predicted (n=37) 93.3 (22;118) 92.3 (56;128) 0.06 -9.2 (-18.9;0.4)
CF-CT bronchiectasis score, % 1.6 (0;22) 2.1 (0;24) 0.03* -0.7 (-1.4;-0.1)
CF-CT airway wall thickening score, % 2.8 (0;26) 3.7 (0;26) 0.21 -0.7 (-1.8;0.4)
CF-CT mucus plugging score, % 2.8 (0;39) 4.2 (0;56) 0.06 -1.9 (-3.9;0.1)
CF-CT opacities score, % 3.7 (0;15) 5.6 (0;13) 0.83 0.1 (-0.8;1.0)
CF-CT trapped air score, % 26.9 (0;76) 32.4 (7;78) 0.03* -6.6 (-12.6;-0.6)
Table 1. Baseline and two year follow up characteristics of the whole study cohort.
Data are presented as no. (%) or median (range). T1 and T2 indicate the 2 time moments. CFRD: CF-
related diabetes. ABPA: Allergic Bronchopulmonary Aspergillose. Chronic colonization Pseudomonas 
aeruginosa	(Pa)	is	defined	as	≥	3	consecutive	positive	respiratory	cultures	for	Pseudomonas	aeruginosa..	# 
SES: socio-economic status based on the highest level of education of the parents (n=36) * Correlation is 
significant	at	the	0.05	level	(2-tailed).	**	Correlation	is	significant	at	the	0.01	level	(2-tailed).
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Correlations between CT and CFQ-R at T1 and T2 (Table 3)
At T1, all CT indices were significantly associated with CFQ-R RSS. Furthermore, CF-CT 
opacities were associated with Physical Functioning.
Similar correlations were found at T2: all CT indices were significantly associated with CFQ-R 
RSS. No significant associations were found between CT indices and Physical Functioning.
T1 T2 Change two years
CFQ-R Child 
Version
(6-13 years) 
(n=29)
CFQ-R Teen/ 
Adult Version 
(≥14	years)	
(n=11)
CFQ-R Child 
Version
(6-13 years) 
(n=17)
CFQ-R
Teen/Adult 
Version
	(≥14	years)	
(n=23)
P-value Mean 
difference 
(CI95%)
CFQ-R RSS 83 (50;100) 89 (61;100) 83 (52;92) 89 (56;100) 0.84 -0.4 (-4.4;3.6)
CFQ-R Phys. 83 (61;100) 96 (67;100) 89 (61;100) 92 (62;100) 0.26 -2.8 (-7.6;2.1)
CFQ-R Vital.# - 67 (50;100) - 67 (50;100) n/a
CFQ-R H.P.# - 67 (11;100) - 78 (11;100) n/a
Table 2. Scale scores of the CFQ-R at T1 and T2.
Data are presented as median (range). T1 and T2 indicate the two time points. 
The selected scale scores of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) are the CFQ-R Respiratory 
Symptoms scale (CFQ-R RSS), CFQ-R Physical Functioning (CFQ-R Phys.), CFQ-R Vitality (CFQ-R Vital.), 
and CFQ-R Health Perceptions (CFQ-R H.P.). #The sample size was too small (n=11) to analyse the change 
in CFQ-R Vitality and CFQ-R Health Perceptions over a two-year time period.
Associations between CT indices, CFQ-R RSS and CFQ-R Physical Functioning at T1 and T2. The CFQ-R 
RSS and CFQ-R Physical Functioning Scale are included in the CFQ-R Child Version and in the Teen/
Adult Version. The CFQ-R Vitality scale and CFQ-R Health Perceptions scale are excluded because of the 
sample	size.	**Correlation	is	significant	at	the	0.01	level	(2-tailed).	*	Correlation	is	significant	at	the	0.05	
level (2-tailed). 
T1 T2
CFQ-R 
RSS(n=40)
CFQ-R Physical 
Functioning 
(n=40)
CFQ-R RSS 
(n=40)
CFQ-R Physical 
Functioning 
(n=40)
CF-CT bronchiectasis score, % -0.49** -0.17 -0.41** -0.12
CF-CT trapped air score, % -0.34* -0.23 -0.37* -0.04
CF-CT airway wall thickening score, % -0.43** -0.19 -0.45** -0.14
CF-CT mucus plugging score, % -0.47** -0.24 -0.46** -0.12
CF-CT opacities score, % -0.37* -0.39* -0.36* -0.10
Table 3. Associations between CT indices and CFQ-R scale scores at T1 and T2.
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Change over time
There was a significant increase in CF-CT bronchiectasis and CF-CT trapped air scores, 
indicating a significant progression of bronchiectasis and trapped air over a two-year time 
period (Table 1, Figure 2). Over two years, the mean progression of bronchiectasis was 
0.7%, and progression of trapped air was 6.6%.
There was no statistical difference between the patients with a worsening in CF-CT bron-
chiectasis scores (n=13) and the ones with stable or improved CF-CT bronchiectasis 
scores (n=27) in: SES (p=0.27), genetics (p=0.24), pancreatic insufficiency (p=0.52), CFRD 
(p=0.19), asthma (p=0.59), ABPA (p=0.14), chronic colonization with Pseudomonas aerugi-
nosa (p=0.16), FEV1 percent predicted at T2 (p=0.19), and CFQ-R RSS scores at T2 (p=0.30). 
Nineteen patients with a worsening in CF-CT trapped air scores and 21 patients with stable 
or improved CF-CT trapped air scores were included in the trapped air subgroup analyses. 
Similar results were found in this subgroup analyses with respect to baseline characteristics: 
SES (p=0.93), genetics (p=0.51), pancreatic insufficiency (p=0.19), CFRD (p=0.49), asthma 
(p=0.13), ABPA (p=0.29), chronic colonization with Pseudomonas aeruginosa (p=0.55), 
FEV1 percent predicted at T2 (p=0.65), and CFQ-R RSS scores at T2 (p=0.84). 
Figure 2. This	fi	gure	shows	over	a	two	year	time	period	in:	a)	a	signifi	cant	progression	in	CF-CT	bronchi-
ectasis	score	(p=0.03);	b)	a	signifi	cant	progression	of	CF-CT	trapped	air	score	(p=0.03);	c)	no	signifi	cant	
change	in	CFQ-R	RSS	(p=0.84),	and	d)	no	signifi	cant	change	in	FEV1	(p=0.14).	T1	and	T2	indicate	the	two	
time points with a time interval of two years. The red line represents the median.
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Furthermore, we did not find a significant change over time in airway wall thickening (Table 
1), mucus plugging (Table 1), opacities (Table 1), CFQ-R RSS (Table 2, Figure 2), Physical 
Functioning (Table 2), or FEV1 (Table 1, Figure 2). No significant correlations were found 
between changes in CF-CT scores, CFQ-R RSS and Physical Functioning (Table 4). 
DIsCUssIon
To our knowledge, this is the first study to evaluate associations between bronchiectasis, 
trapped air and CFQ-R scores, by both cross-sectional and longitudinal analysis. The most 
important findings of this study were that CT indices correlated significantly with CFQ-
R RSS at T1 and T2. Although we found a significant progression of bronchiectasis and 
trapped air over two-years, this was not reflected by lower CFQ-R RSS scores or lower FEV1.
The cross-sectional association between CT and CFQ-R indices at T1 is consistent with 
our previous study (12). Although, this longitudinal study has a considerable overlap in 
patient population with our previous study, we now show that after two-year follow up of 
this cohort, the associations between CT and CFQ-R indices remain similar in strength and 
significance. 
Also consistent with a previous study is the observed progression of bronchiectasis (3). 
De Jong et al. found an average progression of bronchiectasis scores of 1.7% per year in 
children (3). In the current study, we found a substantially lower mean progression of bron-
chiectasis score of 0.7% over two years. Considering the 10 year time difference between 
study periods (1997-2004 versus 2007-2012), it seems likely that less severe progression 
of bronchiectasis is a result of improved treatment and monitoring starting earlier in life. 
We expected that patients with progression of CF lung disease on CT would experience 
more respiratory symptoms. However we did not observe this. There are several possible 
explanations. One possibility is that patients adapt to their worsening of pulmonary dis-
ease. Several previous studies have shown that patients with a chronic disease tend to 
adapt to their disabilities (27). However, an 18-month open-label study of Aztreonam inha-
lation with monthly measurements of CFQ-R and lung function did not show any evidence 
of response shift (28). In addition, a recent study of Sawicki et al. showed that the CFQ-R 
Delta CFQ-R
RSS (n=40)
Delta CFQ-R
Physical Functioning (n=40)
Delta CF-CT bronchiectasis score, % 0.11 0.15
Delta CF-CT trapped air score, % -0.03 0.16
Table 4. No	significant	correlation	between	changes	in	CF-CT	scores,	CFQ-R	RSS	and	Physical	Function-
ing scores.
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RSS was sensitive to changes in respiratory symptoms over a shorter time period of 9-15 
months (18). Our sample size was much smaller and may not have been adequately pow-
ered to detect these changes. Also the variability in CF-CT bronchiectasis scores was lower 
than the variability in CFQ-R RSS (SDS 2.0, SDS 12.4, respectively), indicating that the bron-
chiectasis score was more sensitive than the CFQ-R RSS at detecting a change in this small 
cohort. There was more separate variance than common variance between CT and CFQ-R, 
suggesting that the CFQ-R provides different information than CT. Another possibility is 
that in our study population, progression of bronchiectasis was less severe than the Sawicky 
et al. population and therefore, patients did not perceive a worsening of their symptoms.  
In addition to progression of bronchiectasis, we found a significant progression of trapped 
air. This is consistent with previous studies showing that trapped air progresses over time 
and eventually contributes importantly to severe advanced lung disease (9). In our study, 
progression of trapped air did not result in lower CFQ-R RSS scores. It is possible that 
the extent and progression of irreversible trapped air was small and therefore, did not 
cause more respiratory symptoms. Furthermore, the CFQ-R has a two-week recall window, 
whereas changes on a CT may be detectable over a longer time scale (15,29). An alterna-
tive explanation is that trapped air does not have a negative impact on symptoms. 
In contrast to bronchiectasis and trapped air no significant progression was found in airway 
wall thickening, mucus plugging or opacities. This is partly in concordance with a previous 
longitudinal study performed in our CF cohort including data between 1996 and 2002 (3). 
De Jong et al. also observed no progression in airway wall thickening and opacities over 
two years. However, they did observe a significant progression of mucus plugging (3). That 
we did not observe progression of mucus plugging is likely related to changes in therapy 
over the last decade by our CF team, focusing now more on effective mucociliary clearance 
(30). 
A disadvantage of CT that should always be taken into account is its ionizing radiation 
exposure. The radiation exposure related to our protocol is in the order of one third of the 
annual background radiation exposure in the USA, which is considered low risk.  Similar to 
previous studies, we observed that chest CT is more sensitive to detect progression of CF 
lung disease than FEV1 (5,31). A significant worsening in bronchiectasis and trapped air was 
detected, while FEV1 didn’t change significantly over time. Similar findings were observed 
by de Jong et al. (3) and more recently by Owens et al. (5). Our current study adds further 
support that CT is more sensitive for monitoring disease progression than FEV1.  
Limitations
The data for this longitudinal, retrospectively analyzed study were collected from a sin-
gle center, which may reduce the generalizability of the results. Furthermore, we used an 
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age-range of 6 to 19 years and considering the progressive nature of CF, an association 
between progression in CT and progression in CFQ-R RSS scores may become apparent 
with increasing age. Additionally, the observation period of two years might have been 
too short to detect change in symptoms. Furthermore, two different versions (child and 
adolescent) of the CFQ-R were used at different ages and the sample might have been too 
small to detect changes over time. Data were collected as part of the annual examination. 
During this study period the annual evaluation protocol was changed, to structure the fol-
low up schedule for routine chest CTs, so that every child with CF has a CT at the same age 
(6/8/10/12/14/16/18 years). Therefore we had to exclude 18 patients who did not have two 
CTs between 2007 and 2012. Furthermore data on CFQ-Rs in 13 patients were lost due to 
technical problems. We consider these missing data as completely at random and it is very 
unlikely that this has biased our results.
Conclusion
Our results indicate that bronchiectasis and trapped are sensitive outcome measures in CF 
lung disease. Bronchiectasis and trapped air were significantly correlated with CFQ-R RSS 
at two time points. However, the observed progression of bronchiectasis and trapped air in 
two years was not necessarily associated with changes in quality of life.
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onLIne sUPPLeMent
CT scanning
All volumetric CTs were acquired using a 6-slice multi-detector CT scanner (Siemens Medi-
cal Solutions, Germany). Each CT consisted of a volumetric inspiratory and expiratory ac-
quisition. Instructions for voluntary breath holds were given before scanning. kV tube volt-
ages of 80 (patients < 35 kg) or 110 (patients > 35 kg) were used with a 0.6-sec rotation 
time. Scanning was done from apex to base at 1.5 pitch and 6x2 mm collimation. Images 
were reconstructed with a 3.0 mm slice thickness, 1.2 mm increment and kernel B60s. For 
the inspiratory protocol a modulating current was used (Siemens) with a reference tube 
current-time product of 20 mAs, for optimal image quality. For expiratory CTs, a tube cur-
rent fixed at 25 mA with an effective tube current-time product of 10 mAs was used. This 
yielded a lower radiation dose than the inspiratory protocol, with sufficient image quality. 
Total radiation dose was approximately 1 mSv. 
e-Figure 1.1. Bland Altman of the CF-CT bronchiectasis score. The horizontal lines represent mean and 
±2 SD.
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e-Figure 1.2. Bland Altman of the CF-CT trapped air scores. The horizontal lines represent mean and 
±2 SD.
e-Figure 1.3. Bland Altman of the CF-CT airway wall thickening scores. The horizontal lines represent 
mean and ±2 SD.
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e-Figure 1.5. Bland Altman of the CF-CT opacities scores. The horizontal lines represent mean and 
±2 SD. 
e-Figure 1.4. Bland Altman of the CF-CT mucus plugging scores. The horizontal lines represent mean 
and ±2 SD.
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ABstRACt
Background. CT-detected bronchiectasis and trapped air are important determinants of 
cystic fibrosis (CF).
Objective. To identify predictors of bronchiectasis and trapped air severity after 6 years 
follow up among children ages 6-13 years with CF.
Methods. Single centre longitudinal study. Inclusion: CF patients with two routine volu-
metric CTs obtained 6 years apart, aged 6-13 years at CT1. Predictors tested in univariate 
and stepwise multivariate modelling included: gender, age, socio-economic status, FEV1, 
Pseudomonas aeruginosa infection, pulmonary exacerbations, bronchiectasis and trapped 
air at CT1. 
Results. Twenty-three patients were included; age at CT1 was 9.4 (range 7-13) years. Sig-
nificant predictors for bronchiectasis were: FEV1 (p=0.02); Pseudomonas aeruginosa infec-
tion (p<0.01); bronchiectasis at CT1 (p<0.01). Significant predictors for trapped air were: 
bronchiectasis at CT1 (p=0.05); pulmonary exacerbations (p=0.03); gender (p=0.02). Bron-
chiectasis at CT1 was the strongest predictor for bronchiectasis at CT2; a 1% higher score 
resulted in a 1.03 % higher bronchiectasis score at CT2 (p<0.01). Gender remained predic-
tive for trapped air at CT2; females had a 26.9% higher score than males (p=0.02). 
Conclusion. Bronchiectasis at CT1 was the strongest predictor for bronchiectasis severity at 
CT2, supporting the clinical importance of bronchiectasis. We found female gender to be 
the strongest predictor for trapped air severity.
63
IntRoDUCtIon
In cystic fibrosis (CF), the main cause of morbidity and mortality is progressive obstructive 
lung disease, characterized by bronchiectasis and trapped air detectable by chest-comput-
ed tomography (CT) (1-3). 
Bronchiectasis and trapped air develop early in life (4-9). Recent studies have shown that 
by the age of 3 to 5 years, 50-70% of children with CF have developed bronchiectasis 
(4,6,10). In 75% of young children with CF, progression of bronchiectasis on serial CTs is 
detected by 5 years (4,6,10). The average progression of CF-CT bronchiectasis scores in 
these young children was 1.7% per year (11). Preventing bronchiectasis progression is vital 
because bronchiectasis has a negative impact on lung function (11); pulmonary exacerba-
tions (12,13); mortality (14); quality of life (15), and is an important component of end-stage 
lung disease (14).
Another important component of end-stage lung disease is trapped air (14). Trapped air 
was present in 67% of infants with CF by the age of 3 months (4). Furthermore, trapped air 
is associated with reduced quality of life (15) and mortality (14). 
To prevent progression of CF lung disease it is important to identify early predictors of 
progression of bronchiectasis and trapped air. Several cross-sectional studies have identi-
fied clinical characteristics associated with bronchiectasis and trapped air (4-6). However, 
longitudinal associations have only been studied in the AREST CF studies including chil-
dren up to 6 years of age (4,16). In infants <3 years of age, Sly et al. identified meconium 
ileus, respiratory symptoms, free neutrophil elastase activity in bronchoalveolar lavage fluid 
and trapped air as predictors of bronchiectasis (16). Mott et al. identified similar predictors 
for bronchiectasis in children in this cohort up to six years of age (4). Furthermore, severe 
CFTR genotype and worsening in the BAL inflammatory response score were identified as 
predictors for trapped air (4). To date no predictors of bronchiectasis and trapped air sever-
ity have been studied in a cohort of children over 6 years of age. The aim of our study is to 
identify longitudinal predictors of bronchiectasis and trapped air severity in children ages 
6-13 who underwent two CT scans 6 years apart.
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MetHoDs
Study population
In this retrospective, single centre study we included longitudinally collected data from 
children diagnosed with CF undergoing biennial volumetric CT scans at 6-13 years of age 
(CT1) and approximately 6 years later (CT2) as part of routine clinical care between January 
2004 and February 2012 at the Erasmus MC - CF Centre. 
Children were diagnosed with CF by a positive sweat test and/or genotyping for known 
CF mutations. Children and adolescents receiving intravenous antibiotics for respiratory 
symptoms at their annual examination were considered unstable and were excluded. All 
included patients gave their informed consent for data use. The Institutional Review Board 
of our centre gave approval for the study (MEC-2013-593).
CT acquisition and spirometry
CTs were performed on different CT scanners due to the introduction of newer and faster 
CT scanners and the introduction of low dose CT protocols. In addition, spirometer-con-
trolled CT scanning to optimize inspiratory and expiratory volume, was introduced in our 
hospital in 2007, after all CT1’s were performed (17). Consequently, only CT2 scans were 
performed with spirometer-control. Details about CT acquisition are provided in the on-line 
supplement.
Spirometry was performed using the Jaeger clinical spirometer (Jaeger AG, Würzburg, Ger-
many). The spirometry parameter analysed was forced expiratory volume in 1 sec (FEV1), 
expressed as a percentage of predicted values (% predicted), according to Stanojevic et 
al. (18).
Outcomes and covariates
CTs were de-identified using MyrianÒ (intrasense Montpelier, France), and scored in ran-
dom order. Similar to previous studies, CTs were scored by one observer (observer 1: D.Z.) 
with two years of experience in analyzing CTs with the validated CF-CT scoring system 
(12,14,19). This scoring system evaluates the 5 lung lobes and the lingula for the main 
outcome measures: severity, extent of bronchiectasis (CF-CT bronchiectasis score) on in-
spiratory CTs, and pattern and extent of trapped air (CF-CT trapped air score) on expira-
tory CTs (12,14,19). Other evaluated components of the CF-CT scoring system were: the 
severity and extent of airway wall thickening; mucus plugging; and opacities (atelectasis, 
consolidation). The maximum possible score was 207 points. Sub-scores for bronchiectasis 
and trapped air were expressed as percentages of maximal scores on a 0-100 scale. To 
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test scoring reliability of observer 1 (D.Z.), a second observer with two years of experience 
in CF-CT scoring (A.B.), scored a random subset of 25 CTs. For intra-observer agreement, 
observer 1 (D.Z.) rescored 25 scans after one month in a blinded fashion. 
The following covariates were evaluated as possible predictors of bronchiectasis and 
trapped air severity at CT2: gender; age at CT1; socio-economic status (defined as the high-
est level of education of either parent); FEV1 % predicted at CT1; Pseudomonas aeruginosa 
infection	 (defined	as	≥	1	positive	 respiratory	cultures	 for	Pseudomonas aeruginosa from 
birth to CT1); pulmonary exacerbations (defined as the number of courses of intravenous 
antibiotics in the year prior to CT1 (12,20,21)); and CF-CT bronchiectasis and trapped air 
scores at CT1. 
Statistical analysis
Characteristics at time points CT1 and CT2 were compared using Student’s paired t-tests 
(continuous variables) and Chi-square test (categorical variables). 
Inter- and intra-observer agreement of CF-CT bronchiectasis and trapped air scores were 
calculated using intraclass correlation coefficients (ICC). Although no universally accepted 
standards are available for what constitutes good reliability, ICC values between 0.4 and 
0.6,	 0.6	 and	0.8,	 and	≥	0.8	 are	generally	 considered	 to	 represent	moderate,	good	and	
very good agreement. Systematic errors in component scores were evaluated using Bland-
Altman plots, expressing the differences between two observers as a function of their mean 
(22). 
As a rule of thumb, we did not include >1 variables per n=10 patients in our models. Given 
our sample size all associations were assumed linear, and interaction between predictors 
was not tested for. Linear regression model assumptions were tested in the final models 
and showed no evidence for violation of the assumptions of homoscedasticity and normal-
ity of the residuals. 
All statistical analyses were performed using SPSS version 20.0..Continuous variables are 
reported as medians (ranges). P-values less than 0.05 (two tailed) were considered statisti-
cally significant. There was no adjustment for multiple comparisons.
C
ha
p
te
r 4
66
 
ResULts
Study population
Twenty-three children (17 males) were included in this study. The median age at CT1 was 9.4 
(range 7-13) years and at CT2 15.6 (range 14-20) years. The mean time interval between the 
two CTs was 6.5 (range 5.9-7.9) years. Baseline characteristics of the study population are 
shown in Table 1. All participants were eligible for the bronchiectasis analysis, assessed on 
Characteristic CT1 CT2 p-value Mean difference 
(CI95%)
Gender (Male) 17 73.9
Age, years 9.4 (7; 13) 15.6 (14; 20) 6.5 (6.3; 6.8)
Socio economic status‡
Low 4 17.4
Average 8 34.8
High 8 34.8
Academic 3 13.0
Genetics
Homozygous dF508 11 47.8
Heterozygous dF508 11 47.8
Other 1 4.3
Presence of co-morbidities
Pancreatic insufficient 18 78.3
CF-related diabetes 2 8.7
Asthma 1 4.3
ABPA 0 0
Pseudomonas aeruginosa infection‡‡ 12 52.2
Pulmonary exacerbation (yes/no)# 5 21.7
BMI 16.1 (13; 21)
FEV1, % predicted 84.0 (55; 117) 79.7 (47; 117) 0.07 -5.2 (-10.7; 0.3)
CF-CT bronchiectasis score, % 2.8 (0; 17) 5.6 (0; 29) 0.04* 2.6 (0.1; 5.0)
CF-CT trapped air score, %## 22.2 (0;50) 37.0 (0;89) 0.01* 22.2 (6.1; 38.3)
Table 1. Characteristics of the study cohort (N=23) at baseline (CT1) and follow up (CT2).
Data are presented as no. (%) or median (range). ABPA: Allergic Bronchopulmonary Aspergillosis.  ‡ Based 
on the highest level of education of either parent. ‡‡ Presence of one or more positive respiratory cultures 
for Pseudomonas aeruginosa from diagnosis to CT1 or from diagnosis to CT2. 
# Pulmonary exacerbation 
(yes/no), represents the number of patient who had a pulmonary exacerbation requiring intravenous 
antibiotics in the year prior to the CT. ## n=13 (8 males) for trapped air analysis because not all subjects 
had an expiratory CT at time of CT1.	*	Significance	at	the	0.05	level	(2-tailed).	**	Significance	at	the	0.01	
level (2-tailed).
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the inspiratory scans at CT1 and CT2. The inspiratory CT2 was spirometer-controlled in 15 of 
the 23 children (e-Figure 1, on-line supplement). Thirteen children (8 males) were eligible 
for trapped air analysis, assessed on expiratory scans at CT1 and CT2. The expiratory CT2 
was spirometer-controlled in 6 of these 13 children (e-Figure 1, on-line supplement). 
The ICC for inter-observer agreement for the bronchiectasis score was 0.86 and for trapped 
air 0.72 (e-Figure 2). The ICC for intra-observer agreement for the bronchiectasis score was 
0.87 and for trapped air 0.73.  
Change over time
At CT2 significantly more patients had a Pseudomonas aeruginosa isolated from a respira-
tory culture since birth (p<0.01) and at least one pulmonary exacerbation in the year prior 
(p<0.01) to CT1 (Table 1). We found significant progression of bronchiectasis (mean differ-
ence in bronchiectasis score 2.6, 95% CI 0.1, 5.0, p=0.04) and trapped air (mean differ-
ence in trapped air score 22.2, 95% CI 6.1, 38.3, p=0.01, Table 1, Figure 1) over 6.5-year 
follow-up. A trend was observed for the loss in FEV1 % predicted during follow up (mean 
difference -5.2%, 95% CI -10.7, 0.3, p=0.07). 
Prediction
Statistically significant predictors at CT1 for bronchiectasis at CT2 were (Table 2): FEV1 % 
predicted (p=0.02), Pseudomonas aeruginosa infection before CT1 (p<0.01) and bronchiec-
tasis score (p<0.01). A decline of 1% in FEV1 % predicted was associated with a 0.26% high-
er bronchiectasis score at CT2 (CI95% -0.47 to -0.04). Children with Pseudomonas aeruginosa 
Figure 1. Individual changes in bronchiectasis scores (left panel, n=23) and trapped air scores (right 
panel, N=13) from CT1 to CT 2 (mean interval 6.5 years). The dashed line represents the median scores.
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infection before CT1 had an 8.8% higher bronchiectasis score at CT2 (CI95% 2.4 to 15.0). A 1% 
higher bronchiectasis score at CT1 was associated with a 1.03% higher bronchiectasis score 
at CT2 (CI95% 0.6 to 1.4). These results predict that a patient with a bronchiectasis score at 
CT1 of 3% would have a bronchiectasis score at CT2 of 3.09%. 
Statistically significant predictors at CT1 for trapped air at CT2 were (Table 3): female gender 
(p=0.02), pulmonary exacerbations in the year prior to CT1 (p=0.03), and bronchiectasis 
score at CT1 (p=0.05). Females had on average a 26.9% higher trapped air score at CT2 
than males (CI95% 4.7 to 49.1). Each pulmonary exacerbation in the year prior to CT1 was 
associated with a 27.7% higher trapped air score at CT2 (CI95% 3.8 to 51.5). A 1% higher 
bronchiectasis score at CT1 was associated with a 1.71% higher trapped air score at CT2 
(CI95% 0.1 to 3.4). 
Predictor at CT1 % increase in BE 
at CT2
CI95% P-value
Gender 6.1 -1.9; 14.1 0.13
Age 0.72 -1.5; 2.9 0.50
Socio economic status -0.80 -2.9; 1.3 0.44
FEV1 (% predicted) -0.26 -0.47; -0.04 0.02
*
Pseudomonas aeruginosa infection 8.8 2.4; 15.0 <0.01**
Pulmonary exacerbation in the year prior to CT1 6.6 -2.0; 15.1 0.12
Bronchiectasis score 1.03 0.6; 1.4 <0.01**
Trapped air score# 0.15 -0.3; 0.6 0.45
Table 2. Univariate predictors at CT1 for bronchiectasis (BE) at CT2 (n=23).
# n=13 (8 males) for trapped air analysis because not all subjects had an expiratory CT at time of CT1. * 
Significance	at	the	0.05	level	(2-tailed).	**	Significance	at	the	0.01	level	(2-tailed).
Predictor at CT1 % increase in TA 
at CT2
CI95% P-value
Female gender 26.9 4.7; 49.1 0.02*
Age 3.6 -2.9; 10.0 0.26
Socio economic status -1.7 -8.0; 4.6 0.59
FEV1 (% predicted) -0.36 -1.1; 0.4 0.30
Pseudomonas aeruginosa infection 9.7 -12.1; 31.5 0.37
Pulmonary exacerbation in the year prior to CT1 27.7 3.8; 51.5 0.03
*
Bronchiectasis score 1.7 0.0; 3.4 0.05*
Trapped air score 0.80 -0.7; 2.3 0.28
Table 3. Univariate predictors at CT1 for trapped air (TA) at CT2 (n=13).
*	Significance	at	the	0.05	level	(2-tailed).	**	Significance	at	the	0.01	level	(2-tailed).
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In a backward stepwise multivariate model all the significant predictors from univariate 
analysis were initially included. The weakest predictors were taken out stepwise until only 
independently significant predictors remained. In this analysis the CF-CT bronchiectasis 
score at CT1 was the strongest predictor for bronchiectasis severity at CT2 (CI95% 0.6; 1.4, 
p<0.01) and female gender remained as strongest predictor for trapped air severity at CT2 
(CI95% 4.7;49.1,p=0.02). 
 
DIsCUssIon
This is the first longitudinal study in children with CF over age 6 evaluating risk factors for 
bronchiectasis and trapped air over a 6-year time period. We found that the bronchiectasis 
score at CT1, FEV1 % predicted at CT1 and Pseudomonas aeruginosa infection before CT1 
were predictive of bronchiectasis severity at CT2. However, the effect of the latter two char-
acteristics appeared to be mediated through the bronchiectasis at CT1, which was the only 
independent predictor for bronchiectasis severity 6 years later. The bronchiectasis score at 
CT1, a pulmonary exacerbation in the year prior to CT1, and female gender were identified 
as predictors for trapped air severity at CT2. In backward stepwise multivariate analyses 
female gender was the strongest predictor of trapped air severity 6 years later. 
FEV1 % predicted at CT1 was identified as a predictor for the severity of bronchiectasis at 
CT2. This was expectated, because previous studies showed an association between FEV1 
and the CF-CT bronchiectasis score (12,13,23). Furthermore we showed that Pseudomonas 
aeruginosa infection was a predictor of bronchiectasis severity at CT2, which is consistent 
with a longitudinal study performed in younger children (16). We indicate the CF-CT bron-
chiectasis score at CT1 as the strongest predictor for bronchiectasis severity at CT2. This was 
expected because bronchiectasis is considered to be irreversible (4). CF-CT bronchiectasis 
score at CT1 could predict only 0.03% of the increase in bronchiectasis during the 6-year 
follow-up, and none of the other tested variables could add any predictive value in the 
multivariate model. The fact that we could not identify better predictors for bronchiectasis 
progression may partially be due to the limited sample size. Secondly, there was relatively 
little progression in bronchiectasis over the 6-year study period, which substantially re-
duced the power to detect significant predictors for bronchiectasis progression. We found 
an annual increase in the CF-CT bronchiectasis score of 0.4% in our current cohort, whereas 
previously in our centre in a similar aged cohort using an annual increase of 1.7% was found 
(11). These results suggest that in the 7-year time difference between the two study periods 
(1997-2004 versus 2004-2012) the efficacy of monitoring and treatment of CF lung disease 
may have substantially improved.
The bronchiectasis score at CT1 was also predictive of trapped air severity 6 years later. This 
is not surprising, since bronchiectasis and trapped air are commonly reported together, 
C
ha
p
te
r 4
70
although their pathophysiological relationship remains unclear. In contrast to bronchiec-
tasis scores, trapped air scores at CT1 were not predictive of bronchiectasis or trapped air 
severity. A possible explanation for not identifying trapped air as a predictor might be that 
trapped air has shown to be reversible to some extent (14). 
A pulmonary exacerbation in the year prior to CT1 was identified as a predictor for trapped 
air severity at CT2, which is consistent with findings from the AREST CF cohort performed 
in children aged 0-6 years (4-6). An interesting observation is that female gender was the 
strongest significant predictor of trapped air severity at CT2. Given the small sample size, 
this could be a chance finding. However, gender differences in clinical outcomes have been 
previously reported  (24,25), probably due to the role of sex hormones (25). It is an interest-
ing finding that requires further investigation.
In our relative small cohort bronchiectasis and trapped air severity progressed significantly 
over 6 years. This progression was not accompanied by a significant decrease in FEV1 % 
predicted. This is the third study showing that chest CT is a more sensitive outcome mea-
sure than FEV1 for monitoring progression of lung disease in children, suggesting that chest 
CT could play an important role in clinical care and in clinical trials (11,26),
This study has several limitations. The longitudinal, retrospectively analysed data used in 
this study was collected from a single centre, which may reduce the generalizability of our 
results. Volumetric expiratory CT scanning is the most sensitive protocol for the detection 
of trapped air  (27). Therefore we could only include the expiratory scans for trapped air 
analysis. During the study period CT protocol changes were made to improve image qual-
ity with lower radiation dose and to reduce scanning time. We cannot exclude that the use 
of different CT protocols and scanners might have introduced some noise and reduced 
the strengths of our associations. However, it is well recognized that scoring is relatively 
insensitive to changes in CT scanners and CT scanning protocols (28). Finally, we focussed 
on an age range of 7-20 years, because this is the period of the most rapid decline of lung 
function (29). Considering the progressive nature of CF, other predictors may become ap-
parent with further increase in age. 
The implications of our study in children over age 6 are that there was a reduced observed 
progression of bronchiectasis and trapped air, strongly suggesting that treatment improved 
substantially in the last decade, resulting in better interventions to prevent structural lung 
disease or arrest progression. Identifying bronchiectasis to be irreversible in 6 years suggests 
that randomized controlled trials in young children should focus on the prevention of bronchi-
ectasis. Similar to previous studies, the observed significant progression of bronchiectasis and 
trapped air was not accompanied by a significant decrease in FEV1 % predicted. This strongly 
indicates that CT is a sensitive modality to monitor progression of CF lung disease. Ongoing 
research is focussed on better volume control during CT acquisition, the use of more sensitive 
methods to quantify bronchiectasis, which will most likely further improve the sensitivity of CT. 
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In conclusion, bronchiectasis score at CT1 was identified as the strongest predictor for 
bronchiectasis severity at CT2, while female gender was the strongest predictor for trapped 
air severity 6 years later, supporting the clinical importance of early prevention of bronchi-
ectasis.
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onLIne sUPPLeMent
CT acquisition and scoring
Volumetric CT was introduced in 2004 in our hospital. CTs were performed on different CT 
scanners, due to the introduction of new scanners and low dose CT protocols in the study 
period. CTs made from January 2004 until May 2004 were performed on the single slice 
Prospeed CT scanner (GE SCT Prospeed, General Electric Healthcare, United Kingdom). 
CTs were acquired using 1 mm thick images. Scanning parameters were 120kV, 160 mA 
(≤.9	years	of	age	120	mA),	1-s	scanning	time	and	a	field	of	view	of	350	mm	(≤.9	years	of	
age 250 mm) (1)
In June 2004 they were performed on the 16-slice multi-detector CT scanner (Siemens 
Sensation 16, Siemens Healthcare, Germany). CTs were acquired using 3 mm thick images. 
Scanning parameters were 100kV and the tube current was modulated based on tissue. 
From July 2004 onwards on a 6-slice multi-detector CT scanner (Siemens Emotion 6, Sie-
mens Healthcare, Germany) was used. All CTs made from 2004 onwards consists of a volu-
metric inspiratory acquisition, while only the expiratory CTs made on the GE SCT Prospeed 
scanner (GE SCT Prospeed, General Electric Healthcare, United Kingdom) were volumetric. 
In this study we only used volumetric CTs, therefore we did not include 13 limited cuts ex-
piratory CTs at CT1 (e-Figure 1). 
In 2010, the Definition Flash scanner (SOMATOM Definition Flash, Siemens Healthcare, 
Germany) was introduced. At time of CT2, CTs were predominantly performed on the 
Definition Flash scanner or on the Emotion 6. Three CTs were at CT2 were made on the 
Definition AS+ (SOMATOM Definition AS+, Siemens Healthcare, Germany). Scanning pa-
rameters of the Emotion 6, Definition Flash and Definition AS+ are displayed in e-Table 1.
e-Figure 1. Flowchart of the included CTs, showing the number of patients who had and inspiratory and 
expiratory CT1 en CT2which acquisition was obtained at CT1 and CT2 and which CT2 was spirometer 
controlled.
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According to our volumetric CT scanning protocol instructions for voluntary breath holds 
were given prior to and during scanning. Patients were trained half an hour prior to the CT 
scan, to familiarise the patient with the breathing manoeuvres in supine position. Patients 
were first instructed to breath normally to ensure a tidal breathing pattern. Subsequently 
at inspiratory acquisition, the patient was instructed to fully expire to residual volume, 
followed by maximal inspiration to total lung capacity. After achieving a tidal breathing 
pattern at expiratory acquisition, the patient was instructed to fully inspire to total lung ca-
pacity, followed by a maximal expiration to residual volume. In 2007 spirometer controlled 
CT scanning was introduced to maximize inspiratory and expiratory volume. The majority 
(15/23) of the CT2 scans were spirometer controlled (e-Figure 1). However, if due to logistic 
reasons CT2 could not be spirometer controlled then instructions for breath holds were 
given prior to and during scanning. 
CTs were scored using the CF-CT scoring system. Similar to previous studies, CTs were 
scored by one observer (observer 1) with two years of experience in analyzing CTs with the 
validated CF-CT scoring system (2-4). To test scoring reliability of observer 1, a second ex-
perienced observer with two years of experience in CF-CT scoring, scored a random subset 
of 25 CTs. For intra-observer agreement, observer 1 rescored 25 scans after one month. 
The agreement between the two observers is shown in e-Figure 2.
e-Figure 2. Bland-Altman expressing the inter observer agreement for the CF-CT bronchiectasis and CF-
CT trapped air scores.
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ABstRACt
Background. Bronchiectasis is the most prominent component of cystic fibrosis (CF) lung 
disease but little is known about its development.
Objective. To study the development of bronchiectasis on chest CT and to identify deter-
minants for rapid progression of bronchiectasis. 
Methods. In this single center longitudinal study we included 43 children and adolescents 
with CF who received at least four consecutive biennial volumetric CTs, made between 
January 2005 and July 2013. Areas with bronchiectasis were marked as a region of inter-
est (ROI) on the most recent CT. Using deformable image registration the same ROIs were 
identified in preceding CTs. CTs were de-identified and ROIs were scored randomly. An 
observer indicated for all ROIs whether: bronchiectasis, mucus plugging, airway wall thick-
ening, atelectasis/consolidation, or normal airways was present.
Results. Forty-three patients with 362 ROIs were included. In 187 out of 362 (51.7%) ROIs 
bronchiectasis was persistent in all CTs. For 175 ROIs showing development of bronchi-
ectasis, in 79.4% bronchiectasis developed within 2 years. In 20.6% bronchiectasis was 
preceded by: mucus plugging (17.7%), airway wall thickening (1.7%), or atelectasis/con-
solidation (1.1%). Pancreatic insufficiency was more prevalent in patients showing rapid 
progression (n=21) compared to patients showing slow progression (n=18,p=0.05).
Conclusion. We studied the development of 175 bronchiectatic airways over a time interval 
of maximally 8 years. In 20.6% pre-stages of bronchiectasis could be identified, of which 
mucus plugging was observed most frequently. Most bronchiectatic airways developed 
within a time interval of 2 years without pre-stages, underlining the treacherous nature of 
CF lung disease.
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IntRoDUCtIon
The most prominent component of cystic fibrosis (CF) lung disease is bronchiectasis (1). 
Bronchiectasis is a permanent and irreversible abnormal dilatation of the bronchial lumen 
and is most reliably detected by chest-computed tomography (CT) (2-5). 
Bronchiectasis has been observed on chest CT in infants with CF as young as 10 weeks of 
age (6-11). At 3 to 5 years of age, 50-70% of children with CF already have bronchiectasis, 
which is the main cause of morbidity and mortality in CF (6,8,12). To prevent the develop-
ment of bronchiectasis it is of great clinical importance to identify early pre-stages on CT 
with the aim to prevent further progression. Mucus plugging, airway wall thickening and 
atelectasis or consolidation have been shown to be important components of end-stage 
lung disease and might therefore be eligible pre-stages (1). Studies showed that if bronchi-
ectases are present, they progressively develop (1,6,10,13,14). However, it remains unclear 
how bronchiectatic airways evolve and why progression is more rapid in some patients (15). 
Therefore this study aims to identify pre-stages of bronchiectasis in CF on chest CT and to 
determine which patients are at risk for a rapid progression of bronchiectasis. 
MetHoDs
Study population
This retrospective study used longitudinally collected clinical data from the routine annual 
evaluation of CF patients under treatment in the Erasmus MC-CF Center (Rotterdam, the 
Netherlands) from January 2005-May 2013. We included clinically stable CF patients who 
had at least four consecutive volumetric inspiratory CTs, to guarantee a minimum follow up 
period of six years. A routine chest CT is performed biennially as part of the annual evalu-
ation program. During this study period the annual evaluation program was changed, to 
structure the follow up schedule for routine chest CTs, so that every child with CF has a CT 
at the same age (6/8/10/12/14/16/18 years).
Patients who had a lung transplant in the study period were excluded. Furthermore, if at 
time of CT scanning patients had a pulmonary exacerbation, defined as receiving intrave-
nous antibiotics for respiratory symptoms, or had pulmonary complications (e.g. pneumo-
thorax or hemoptysis) they were considered to be unstable and excluded. 
We denoted the most recent available volumetric CT made during annual evaluation as 
CTbaseline. CTminus1;minus4 are denoted as respectively the first, second, third, and fourth CT 
prior to CTbaseline. This study was approved by the Institutional Review Board of the Erasmus 
MC-CF Center (MEC-2013-593).
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CT acquisition and spirometry
CTs were performed on different CT scanners using different protocols, due to the intro-
duction of a new CT scanner and new low dose CT protocols in the study period.  More 
details about the CT acquisition and CT scanners are given in the on-line supplement.
From 2007 onwards, most volumetric CTs were spirometer controlled. Spirometry con-
trolled CT scanning was introduced in our hospital to optimize inspiratory and expiratory 
volume. If due to logistic reasons CT was not spirometer controlled, then training for breath 
holds prior to the scan and instructions during the scan were given by the lung function 
technician (on-line supplement). Spirometry was performed at the annual evaluation using 
a diagnostic system (Jaeger AG, Würzburg, Germany). The spirometry parameters included 
for analysis were Forced expiratory volume in 1 sec (FEV1) and Forced Vital Capacity (FVC). 
FEV1 and FVC were expressed as percentage of predictive values, calculated using the 
Stanojevic et al. reference equations (16).
CT analyses 
According to the definition of the validated CF-CT scoring system (17-19), bronchiectasis is 
present if the bronchial lumen diameter is larger than the adjacent pulmonary artery outer 
diameter, or if there is a lack of tapering for at least 2 cm distal to a branching point. Based 
on literature about the pathophysiology of bronchiectasis and based on the expertise of a 
panel consisting of a pediatric pulmonologist (HT), a radiologist (PC), a biomedical imaging 
expert (MB), and a PhD student (LT), five mutually exclusive categories to classify pre-stages 
of bronchiectasis were identified. These categories were: 1) bronchiectasis, 2) mucus plug-
ging, 3) airway wall thickening, 4) atelectasis or consolidation, and 5) normal airways. These 
categories are well defined as part of the CF-CT scoring system and are further explained 
in the on-line supplement (17-19).
CTs were de-identified and randomized. One observer (observer 2: DZ) encircled all areas 
with bronchiectasis (bronchial lumen diameter-pulmonary artery outer diameter ratio > 2 
or saccular bronchiectasis) in the most recent volumetric inspiratory CT (CTbaseline). Those 
areas were marked as a region of interest (ROI) using tools in our image analysis platform 
(®Myrian Onco XL, Intrasense, France). By using deformable image registration, the same 
areas were automatically identified in the previous CTs (CTminus1;minus4). All preceding ROIs 
were assessed by two experienced observers with respectively 1 and 2 years of experience 
(HO and DZ) and assigned to one of the five above-mentioned categories. ROIs were as-
sessed in complete random order with respect to patients and order of CT-scans (minus1 to 
minus4). Therefore, the observers had no knowledge on the assigned category of the ROI’s 
in previous or later scans. 
81
Statistical analysis
To assess observer agreement kappa scores were calculated. For the inter-observer agree-
ment, a random subset of 35 patients with a total of 1230 ROIs were scored by two observ-
ers (H.O. and D.Z.). For the intra-observer agreement, a subset of 20 patients with 194 ROIs 
were rescored by H.O. after one month. In the final analyses, only the scores of observer 
H.O. were used. Although no universally accepted standards are available for what consti-
tutes	good	agreement,	kappa	scores	of	<	0.40,	between	0.4	and	0.75,	and	≥	0.75	are	con-
sidered to represent poor, moderate to good and excellent agreement, respectively (20).
Descriptive statistics were used to characterize the evolving patterns of bronchiectasis. 
We calculated how often bronchiectasis was persistent in all CTs and how often it was 
directly preceded by mucus plugging, airway wall thickening, atelectasis/consolidation, or 
normal airways. 
In order to distinguish patients who rapidly developed bronchiectasis from previously nor-
mal airways from the ones who were likely to have a pre-stage, we created two progression 
groups: a rapid progression group and a slow progression group. The number of ROIs in 
which bronchiectasis was directly preceded by normal airways in any two successive scans 
was calculated. The median number of these rapidly progressing ROIs per patient was 
calculated (median=3) and used as the cut-off point to define the groups of rapid and slow 
progressors. Patients who had more than 3 ROIs in which normal airways became bronchi-
ectatic within two years were thus included into the rapid progression group (n=21); the 
others were included in the slow progression group (n=18). The two groups were compared 
with respect to baseline characteristics using Chi square tests. 
SPSS version 13.0 was used for the analyses in this study. Values are shown as median 
(range) unless otherwise indicated. P-values < 0.05 (two tailed) are considered to be statis-
tically significant.
ResULts
Study population and CT data
Forty-three patients were included (Figure 1). Of those 43 patients, 39 patients had 4 con-
secutive CTs and 4 patients had 5 consecutive CTs. The median interval between two CTs 
was 2.0 years (range 0.8-3.9). Baseline characteristics of the study cohort are shown in Table 
1. 
In the CTbaseline of the included 43 patients, 367 unique ROIs were identified. In 5/367 (1.4%) 
ROIs, bronchiectasis turned into a different category before being scored as bronchiec-
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tasis in the baseline scan,  In 
3 of the 5 cases the following 
pathway was identified: bron-
chiectasis in which the CT im-
mediately preceding the CT 
with bronchiectasis showed: 
normal airways; mucus plug-
ging; bronchiectasis; normal 
airways. In 2 of the 5 cases the 
following pathway was identi-
fied: bronchiectasis in which 
the CT immediately preced-
ing the CT with bronchiectasis 
showed: atelectasis/consoli-
dation; bronchiectasis; normal 
airways.
Previous literature showed 
that bronchiectasis are irre-
versible and therefore we ex-
cluded those 5/367 cases from 
further analysis. An overview 
of the structural lung damage 
(CTbaseline;CTminus4) in our study 
period is shown in Figure 2.
The kappa for inter-observer 
agreement was 0.48 and for intra-observer agreement 0.77. The between and within ob-
server agreement is displayed in Table 2.
Bronchiectasis and pre-stages (Figure 2)
In 187 of the 362 (51.7%) ROIs bronchiectasis was persistent in all available CTs. For the 
remaining 175 ROIs in which development of bronchiectasis could be observed, the CT 
immediately preceding the first CT with bronchiectasis showed: normal airways (139/175, 
79.4%); mucus plugging (31/175, 17.7%); airway wall thickening (3/175, 1.7%), or atelecta-
sis/consolidation (2/175, 1.1%). 
The most commonly identified pre-stage of bronchiectasis was mucus plugging. In 23 ROIs 
mucus plugging turned into bronchiectasis within 1 CT (2 years, range 1.7-2.4). In the other 
8 ROIs mucus plugging persisted for 2 CTs (4 years, range 3.7-5.9) before progression to 
Figure 1. Flowchart of the study population.
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bronchiectasis. Mucus plugging never remained longer than 3 consecutive CTs, without 
progressing to bronchiectasis.
Progression to bronchiectasis
Based on the median number of 3 ROIs per patient that progressed from normal to bron-
chiectasis in two years, we included 21 patients in the rapid progression group and 18 
patients in the slow progression group. There was no statistical difference between those 
groups in gender (p=0.47), socio-economic status (p=0.49), genetic defect (p=0.78), CF-
related diabetes (CFRD, p=0.16), asthma (p=0.12), Allergic Bronchopulmonary Aspergillo-
sis (ABPA, p=0.12) or chronic Pseudomonas aeruginosa infection (p=0.39).  However, there 
was a borderline significant difference (p=0.05) for pancreatic insufficiency: all patients 
included in the rapid group were pancreatic insufficient, while 15 of the 18 patients in the 
slow progression group were pancreatic insufficient. 
 
Figure 2. Structural lung damage over time (n=362 in 43 patients).  bronchiectasis,  mucus plugging,  
airway wall thickening,  atelectasis/consolidation,  normal airways. CTbaseline is the most recent CT. 
Percentages are only displayed if they are over 1% .
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DIsCUssIon
This is the first longitudinal study of CT diagnosed bronchiectasis aiming to identify CT 
detectable pre-stages of bronchiectasis in children with CF. We assessed the evolution of 
uniquely identified ROIs using a deformable image registration technique. Our observa-
tions provide a unique insight into the radiologic course of developing bronchiectasis.
Our most important findings are that most bronchiectases appeared within the 2-year time-
frame between successive scans. Of the pre-stages that could be identified, mucus plug-
ging was the most common predecessor of bronchiectasis.
Mucus plugging was identified as a pre-stage of bronchiectasis. Although no previous stud-
ies identifying pre-stages of bronchiectasis have been performed, a previous study from 
our group identified mucus plugging as an indicator for bronchiectasis 6 years later (21). 
Those results suggest that there might be an apparent transition from mucus plugging to 
bronchiectasis, implying that an optimal mucociliary clearance treatment in order to pre-
vent bronchiectasis is important in the management of CF. 
Observer 2
BE MP AWT A/C Normal
O
bs
er
ve
r 1
BE 866 25 10 17 58
MP 8 24 1 1 5
AWT 2 0 0 0 2
A/C 4 1 0 2 0
Normal 68 14 12 4 106
Observer 1
BE MP AWT A/C Normal
O
bs
er
ve
r 1
BE 154 0 0 0 0
MP 1 1 0 0 0
AWT 0 0 0 0 0
A/C 1 1 0 1 0
Normal 10 0 1 0 25
Table 2. Observer agreement.
Left: agreement between observer 1 and 2 over a random subset of 1230 regions of interest (kappa 0.48). 
Right: within-observer agreement of observer 1 over a random subset of 194 regions of interest (kappa 
0.77). BE: bronchiectasis, MP: mucus plugging, AWT: airway wall thickening, A/C:  atelectasis or consoli-
dation, Normal: no abnormalities.
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Development of bronchiectasis without clearly identifiable pre-stages two years earlier was 
commonly seen in this study, suggesting that the development of most bronchiectasis is 
an acute process and not caused by a slow continuous progressive transition. To identify 
risk factors for the acute development of bronchiectasis in our relatively small single center 
cohort, we divided our patients into a rapid and slow progression group. This sub-group 
analysis showed only borderline significant difference in baseline characteristics between 
the pancreatic status in the two groups. All patients in the rapid progression group were 
pancreatic insufficient, versus 80% of the patients in the slow progression group. The im-
portance of pancreatic status as a marker of disease severity has been observed in other 
studies (6,22). Although we could not identify an association between severe CFTR geno-
type and progression of bronchiectasis in our cohort aged 9-24 years, we must acknowl-
edge our small sample size, which may have resulted in inadequate power to detect this 
association. Previous research by Mott et al. did observe a significant association between 
genotype and bronchiectasis progression in children below the age of 6 years (6). 
To gain further insight into the pathophysiology of bronchiectasis, it would be interesting to 
also include trapped air in the analyses; given that an association between trapped air and 
persistence or progression of bronchiectasis has recently been shown in young children 
with CF (6). The most sensitive method to detect trapped air is an expiratory spirometer-
controlled CT (23). For our current study, we did not have sufficient spirometer controlled 
expiratory CTs to include this analysis. 
There are some limitations to this study. The longitudinal, retrospectively analysed data 
used in this study were collected from a single centre, which may reduce the generalizability 
of our results. Data were collected as part of the annual evaluation. During the study period 
our annual evaluation protocol changed to improve the structure of the follow up schedule 
for routine chest CTs so that every child has a CT at the same age (2/4/6/8/10/12/14/16/18 
years) resulting in a larger time range between two CTs for some patients. CTs were per-
formed on different CT scanners, due to the introduction of newer and quicker CT scan-
ners. Furthermore, CT protocols changed in our study period to low dose CT protocols and 
spirometer controlled CT scanning, to reduce radiation and improve image quality (23). 
We cannot exclude that the use of these different CT scanners and CT protocols may have 
reduced the strengths of our associations. Despite this, it is well recognized that the use 
of scoring systems is relatively insensitive to these changes (24). As our study is the first to 
identify ROIs and retrospectively assess the status of these regions in the years preceding 
bronchiectasis, this scoring method has not been used in other studies. The intra-observer 
variability of the scores obtained with this scoring method was moderate to good with 
a kappa of 0.77. This suggests that the scores are reproducible within one observer. A 
disadvantage of our scoring method is that we may have missed more subtle changes in 
airway wall thickening. Scoring is not considered a very sensitive and reproducible method 
to quantify airway wall thickening (19); in most CT scoring studies the kappa for airway wall 
thickening is low. It is well possible that when using more sensitive automated methods to 
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assess airway wall thickening, in the future subtle airway wall thickness might be picked up 
as a pre-stage of bronchiectasis. 
Clinical implication
Our study shows the treacherous nature of CF lung disease in a cohort of patients who 
are receiving standards of treatment as in the majority of cases bronchiectasis developed 
within two years without identifiable pre-stages. The only pre-stage that was identified 
in 17.7% of bronchiectasis was mucous impaction. Hence, this observation in a patient 
warrants close attention by the CF team to further improve mucociliary clearance. Further-
more, our results suggest that in some patients the development of bronchiectasis can oc-
cur rapidly. The identification of pre-stages of bronchiectasis at an early time might create 
a treatment opportunity before irreversible bronchiectasis occurs. Therefore, an annual CT 
may be considered in children with a rapid progression of bronchiectasis. Nevertheless, 
additional studies are needed to identify the risk factors leading the sudden development 
of bronchiectasis. Next, clinical intervention studies are needed that aim to prevent this 
‘sudden’ development of bronchiectasis. 
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onLIne sUPPLeMent 
CT acquisition 
CTs were performed on 6 different CT scanners, due to the introduction of new and faster 
scanners that allowed reducing radiation dose for our clinical chest CT protocol in the study 
period. 
The included CTs (77.8%) were predominantly performed on the Emotion 6 (Siemens Emo-
tion 6, Siemens Healthcare, Germany). In 2010, the Definition Flash scanner (SOMATOM 
Definition Flash, Siemens Healthcare, Germany) was introduced. In total 18.8% (33/176) of 
the included CTs were performed with the Definition Flash scanner (SOMATOM Definition 
Flash, Siemens Healthcare, Germany). The remaining 4% was performed on respectively 
the Definition AS+ (SOMATOM Definition AS+, Siemens Healthcare, Germany), the Defi-
nition Edge (SOMATOM Definition Edge, Siemens Healthcare, Germany), the Sensation 
16 scanner (Siemens Sensation 16, Siemens Healthcare, Germany), and on the Biograph 
(Siemens Biograph, Siemens Healthcare, Germany).
Scanning parameters of the Definition Flash, Emotion 6, and Definition AS+ are displayed 
in e-Table 1. Regarding the other CT scanners, CTs were acquired using 3 mm thick images. 
Scanning parameters were 100kV and the tube current was modulated based on tissue. 
For our spirometer controlled volumetric CT scanning protocol, patients were trained half 
an hour prior to the CT scan, to familiarise the patient with the spirometer and breathing 
manoeuvres in supine position. Patients were first instructed to breath normally to ensure 
a tidal breathing pattern. Subsequently for the inspiratory acquisition, the patient was in-
structed first to fully expire to residual volume, followed by maximal inspiration to total lung 
capacity. After the inspiratory manoeuvre the patient resumed tidal breathing. Next, the 
patient was instructed to fully inspire to total lung capacity, followed by a maximal expira-
tion to residual volume. In 2007 spirometer controlled CT scanning was introduced, to op-
timize inspiratory and expiratory volume.  In our study population, the majority (74.4%) of 
the included CTbaseline scans were spirometer controlled. However, if due to logistic reasons 
CTbaseline could not be spirometer controlled, then training for breath holds prior to scanning 
and instructions during scanning were given by the lung function technician.
CT analyses
According to the definition of the well-validated CF-CT scoring system (18-20), bronchi-
ectasis was present if the bronchial lumen diameter is larger than the adjacent pulmonary 
artery outer diameter, or if there was a lack of tapering for at least 2 cm distal to a branching 
point (e-Figure 1.1). Based on literature about the pathophysiology of bronchiectasis and 
based on the expertise of a panel consisting of a pediatric pulmonologist, a radiologist, a 
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biomedical imaging expert and a PhD student (MD), we identified five mutually exclusive 
categories to classify pre-stages of bronchiectasis were identified. These categories were: 
1) bronchiectasis, 2) mucus plugging, 3) airway wall thickening, 4) atelectasis or consolida-
tion, and 5) normal airways (17-19).
The first category is the pres-
ence of bronchiectasis, defined 
according to the above-men-
tioned definition. The second 
category is mucus plugging. 
Mucus plugging is defined as 
complete or incomplete filling 
of clearly identifiable bronchi, 
resulting in abnormal branch-
ing structures or centrilobular 
nodules in a rosette pattern or 
tree-in-bud sign (e-Figure 1.2). 
The third category is the pres-
ence of airway wall thickening, 
which is defined as the ratio be-
tween the bronchial wall thick-
ness and the outer diameter of 
the adjacent pulmonary artery 
being more than 33% (e-Figure 
1.3). The fourth is the presence 
of atelectasis or consolidation. 
The last category includes nor-
mal airways.  
e-Figure 1.1. Different features of bronchiectasis. Figure 1.1a shows cylindric bronchiectasis. The upper 
arrow indicates the bronchiectasis and the lower arrow indicates the corresponding vessel. Figure 1.1b 
shows saccular bronchiectasis. The upper arrow indicates the corresponding vessel and the lower arrow 
indicates the saccular bronchiectasis. Figure 1.1c shows a lack of normal bronchial tapering for at least 2 
cm, as indicated by the arrow.
e-Figure 1.2. Illustration of scoring category: mucus plugging. 
The	arrow	in	image	1.2a	indicates	a	mucus	filled	bronchus.	In	
Figure 1.2b it indicates the rosette pattern. The arrow in Figure 
1.2c indicates the tree-in-bud sign and in Figure 1.2d it indi-
cates	a	small	mucous	filled	branching	structure.
C
ha
p
te
r 5
92
CTs were de-identified and ran-
domized. One observer (ob-
server 2: D.Z.) encircled all areas 
with bronchiectasis in the most 
recent volumetric inspiratory 
CT (CTbaseline). Those areas were 
marked as a region of inter-
est (ROI) using tools in our im-
age analysis platform (®Myrian 
Onco XL, Intrasense, France). 
By using deformable image reg-
istration, the same areas were 
automatically identified in the 
previous CTs (CTminus1;minus4). All 
preceding ROIs were assessed 
by two experienced observers with respectively 1 and 2 years of experience (HO and DZ) 
and assigned to one of the 5 above-mentioned categories. In case in a particular ROI more 
than one of the above mentioned categories was present, the following rating was appli-
cable: bronchiectasis and mucus plugging were rated as bronchiectasis; bronchiectasis and 
airway wall thickening were rated as bronchiectasis; and if in our region of interest mucus 
plugging and airway wall thickening were present, this was rated as mucus plugging. ROIs 
were assessed in complete random order with respect to patients and order of CT-scans 
(minus1 to minus4). Therefore, the observers had no knowledge on the assigned category 
of the ROI’s in previous or later scans. 
e-Figure 1.3. Illustration of scoring category: airway wall thick-
ening. In e-Figure 1.3a the left arrow indicates a vessel and the 
right arrow indicates airway wall thickening of a central airway. 
In e-Figure 1.3b the left arrow indicates a vessel and the right 
arrow indicates peripheral wall thickening.
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ABstRACt
Background. Computed Tomography (CT) is the gold standard to assess bronchiectasis 
and trapped air in cystic fibrosis (CF) lung disease, but has the disadvantage of radiation 
exposure. Magnetic Resonance Imaging (MRI) is a radiation free alternative. 
Objective. To validate MRI as outcome measure by; correlating MRI scores for bronchiec-
tasis and trapped air with clinical parameters, and by comparing those MRI scores with CT 
scores.
Methods. In patients with CF (aged 5.6-17.4 years), MRI and CT were alternated annu-
ally during routine annual check-ups between July 2007 and January 2010. Twenty-three 
children had an MRI performed one year prior to CT, 34 children had a CT one year prior 
to MRI. Bronchiectasis and trapped air were scored using the CF-MRI and CF-CT scoring 
system. CF-MRI scores were correlated with clinical parameters: FEV1, Pseudomonas ae-
ruginosa, pulmonary exacerbations and patient-reported respiratory symptoms measured 
on the Cystic Fibrosis Questionnaire-Revised (CFQ-R), using Spearman's correlation coef-
ficient. MRI and CT scores were compared using intra-class correlation coefficients (ICC) 
and Bland-Altman plots. 
Results. Fifty-seven patients who had an MRI, CT and CFQ-R during the study period were 
included. CF-MRI bronchiectasis correlated with FEV1, Pseudomonas aeruginosa, pulmo-
nary exacerbations and patient-reported respiratory symptoms. CF-MRI trapped air only 
correlated with FEV1 and Pseudomonas aeruginosa. ICCs between MRI and CT bronchiec-
tasis and trapped air were 0.41 and 0.35 respectively. MRI tended to overestimate bronchi-
ectasis compared to CT. 
Conclusion. The associations between CF-MRI scores and several important clinical pa-
rameters further contributes to the validation of MRI. MRI provides different information 
than CT. 
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IntRoDUCtIon 
Cystic fibrosis (CF) is a common hereditary disease, found mainly in Caucasian populations, 
and has a broad spectrum of disease severity (1). Life expectancy is limited to approxi-
mately 38 years, primarily due to end stage lung disease which is characterized by bron-
chiectasis and trapped air  (1,2). Bronchiectasis reflects irreversible widening of the airways 
and trapped air is indicative for small airway disease. Both can already be observed in early 
childhood (3-5) and despite intensive treatment, bronchiectasis and trapped air progress 
slowly throughout life (1). Accurate and sensitive monitoring of bronchiectasis and trapped 
air is important for clinical management and research (6).
Chest Computed Tomography (CT) is considered to be the gold standard to detect and 
monitor bronchiectasis and trapped air in CF  (7,8). Despite the development of low-radi-
ation-dose volumetric CT scanning protocols, the repeated use of CT is restricted due to 
ionizing radiation  (9,10). Therefore it is desirable to develop chest Magnetic Resonance 
Imaging (MRI) as a radiation free alternative for monitoring CF lung disease (11). 
Many studies have been conducted to improve the image quality of MRI (12). Unfortunate-
ly, despite those improvements, MRI is still considered less sensitive than CT for detecting 
and monitoring bronchiectasis and trapped air (17). More importantly, in contrast to CT, 
only a few studies have validated bronchiectasis and trapped air as assessed by MRI as an 
outcome measure for CF lung disease. It has been shown that bronchiectasis and trapped 
air, assessed by CT, are associated with: FEV1 (13), pulmonary exacerbations  (14,15), and 
patient-reported respiratory symptoms measured with the standardized, well-validated 
Cystic Fibrosis Questionnaire-Revised (CFQ-R)  (16,17). 
We aim to further validate MRI as an outcome measure by: 1) investigating the associa-
tions between MRI scores for bronchiectasis and trapped air and clinical parameters as 
FEV1, Pseudomonas aeruginosa, pulmonary exacerbations and patient-reported respira-
tory symptoms; 2) comparing MRI scores for bronchiectasis and trapped air with CT scores.
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Study population
Clinically stable CF patients (aged 6-20 years) who were treated in the Erasmus MC-Sophia 
Children’s Hospital (Rotterdam, the Netherlands) and had a chest MRI or chest CT, spirom-
etry and CFQ-R performed as part of their annual evaluation between July 2007 and Janu-
ary 2010 were included. In this annual evaluation, a chest MRI is alternated with a chest 
CT, resulting in a CT and MRI in all children within a one-year interval. Children in need of 
intravenous antibiotics for respiratory signs or symptoms at the time of the annual exami-
nation were considered unstable and excluded. This analysis of prospectively collected, 
routine data on the Sophia Children’s cohort was approved by the ethical review board of 
the Erasmus MC-Sophia Children’s Hospital (MEC 2011-460). 
Imaging protocols - MRI and CT
According to our protocol, at the annual evaluation, a MRI was performed at ages 
7/9/11/13/15/17 years. All MRI scans were performed using a 1.5T unit (Excite HD, software 
release 12, General Electric Healthcare, Milwaukee, WI). Six breath-hold scans of maximum 
10 s were done in all orthogonal planes (axial, coronal, and sagittal), covering the whole 
lung region, during full inspiration and end-expiration. 
According to our imaging protocol, at the annual evaluation, a CT was made at ages 
6/8/10/12/14/16/18. All volumetric inspiratory and expiratory CTs were acquired using a 
6-slice multi-detector CT scanner (Somaton Emotion, Siemens Medical Solutions, Erlangen, 
Germany). Instructions for voluntary breath holds were given before scanning or the CT 
was spirometry controlled. A detailed scanning protocol for MRI and CT is displayed in the 
on-line supplement.
Imaging analysis – MRI and CT scans
All MRI and CT scans were anonymized and scored in random order by 1 observer blinded 
to clinical background, using MyrianÒ (intrasense Montpelier, France) (14). A different ob-
server scored MRI and CT scans because they were not specifically trained for the MRI.
The CF-MRI scoring system was used to analyze the MRI images. This scoring system was 
set up using the same methodology as the CF-CT scoring system (see below). This scoring 
system has been used in previous studies and shown to be applicable to MRI  (11,18). The 
severity and extent of central and peripheral bronchiectasis and extent of trapped air were 
scored. The pattern of trapped air with the CF-MRI scoring system was not scored, because 
this was previously shown to be unreliable (18). A composite score for bronchiectasis was 
101
calculated, expressing bronchiectasis as a percentage of a maximum score, on a 0-100 
scale. A sum score for trapped air was calculated by summing up the trapped air scores of 
the 5 lobes and lingula. Higher scores indicated more trapped air.
CTs were scored using the CF-CT scoring system; an upgraded scoring system originally 
derived from the Brody II scoring system  (14,19,20). This scoring system evaluates the 5 
lung lobes and lingula as the sixth lobe. In this study we scored the severity and extent 
of central and peripheral bronchiectasis on inspiratory CTs and the pattern and extent of 
trapped air on expiratory CTs. CF-CT composite scores for bronchiectasis and trapped air 
were calculated and expressed as a percentage of the maximum possible score, on a 0-100 
scale. 
Cystic Fibrosis Questionnaire-Revised (CFQ-R)
CFQ-R questionnaires were completed at every annual evaluation. The Dutch CFQ-R com-
prises three different versions: 1) the CFQ-R Child Version, for children aged 6-13 years; 
2) the CFQ-R Adolescent/Adult Version, for ages 14 and older; and 3) the CFQ-R Parental 
Version, for parents of children aged 6-13 years. We did not include the CFQ-R Parent Ver-
sion in our analyses because the FDA and European Medicines Agency prefer use of the 
patient’s own report on his/her symptoms (21).  
Several domains of the CFQ-R have been shown to correlate with FEV1 (13, 21) (e.g. Respi-
ratory Symptoms scale, Physical Functioning scale, Vitality scale, and Health Perceptions), 
but for sample size reasons and because the Respiratory Symptoms scale most specifically 
reflects lung disease we only included this scale in our analysis. Responses to items on the 
Respiratory Symptoms scale were standardized into a score ranging from 0 to 100, with 
higher scores indicating better health-related quality of life.
Spirometry and pulmonary exacerbations
Spirometry was performed at every annual evaluation using a diagnostic system (Jaeger 
AG, Würzburg, Germany). Results were expressed as percentages of predictive values, ac-
cording Stanjonevic et al. for FEV1 and the forced vital capacity (FVC) (22). 
Because there is no consensus on the definition of pulmonary exacerbations, they were 
conservatively defined as: episodes of treatment with IV antibiotics for pulmonary indi-
cations in the year following administration of CT/CFQ-R or MRI/CFQ-R. Pseudomonas 
aeruginosa ever was defined as the presence of one or more positive respiratory cultures 
previous to the MRI or CT scan.
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Statistical analysis
To validate MRI, we correlated CF-MRI bronchiectasis and trapped air with clinical param-
eters assessed at the same time using Spearman's correlation coefficient: FEV1; pulmonary 
exacerbations; Pseudomonas aeruginosa ever or never before MRI; and patient-reported 
respiratory symptoms. Correlations with these clinical parameters were also calculated for 
CF-CT bronchiectasis and trapped air. According to Cohen’s criteria (1988) correlations with 
a R2 between 0.10 and 0.29 are considered weak, between 0.30 and 0.49 moderate and 
above 0.50 as strong. Intra-observer agreement of CF-MRI scores and CF-CT scores were 
calculated using intraclass correlation coefficients (ICC). ICC values between 0.40 and 0.60, 
0.60	and	0.80,	and	≥	0.80	are	considered	 to	 represent	moderate,	good	and	very	good	
agreement, respectively.
For the comparison of MRI and CT, these investigations were performed within one year. 
The order in which MRI and CT were performed was expected to be random. To assess this, 
the two groups (MRI-CT vs. CT-MRI) were compared with respect to baseline characteristics 
using Chi-square and unpaired t-tests. Spearman’s correlation coefficient and ICC were 
then used to compare CF-MRI and CF-CT bronchiectasis scores and trapped air scores, and 
agreement was visually inspected using Bland-Altman plots (23). 
Statistical analyses were performed using SPSS version 20.0 for windows and SAS version 
9.2. Continuous variables are displayed as median (range) unless defined otherwise. P-
values less than 0.05 (two tailed) were considered statistically significant.
N (%) or median (range)
Number of patients 57 (100%)
MRI in first year – CT in second (%) 23 (40.4%)
Male gender  (%) 29 (50.9%)
Pulmonary exacerbation (%) 18 (31.6%)
Pseudomonas aeruginosa (%) 42 (73.7%)
Age baseline, years 13.0 (5.6-17.4)
Age at CT scan, years 13.2 (5.6-17.7)
Age at MRI scan, years 13.5 (6.6-18.6)
FEV1, % predicted 86.2 (30.3-111.5)
FVC, % predicted 95.1 (53.9-119.4)
Respiratory symptoms on CFQ-R (n=57) 83.0 (39-100)
Respiratory symptoms on child CFQ-R (n=36) 83.0 (58-100)
Respiratory symptoms on adolescent CFQ-R (n=21) 78.0 (39-100)
A pulmonary exacerbation was present if treated with intravenous antibiotics in the year before baseline 
imaging. Pseudomonas aeruginosa, refers to the presence of Pseudomonas aeruginosa ever in a sputum 
culture before imaging was performed.
Table 1. Baseline characteristics of the study population. 
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Study population
We included 57 patients (29 male, 28 female) who had a MRI and CT during the study 
period. Baseline characteristics of the study population are shown in Table 1. Twenty-three 
patients had an MRI performed prior to CT (MRI-CT group), the MRI was performed (me-
dian) one year (range 0.9-2.0 years) prior to CT. In 34 patients a CT was performed prior 
to the MRI (CT-MRI group) with a median time interval of 1.0 year, (range 0.9-3.0 years). 
There were no statistical difference between the MRI-CT group and the CT-MRI group with 
respect to clinical variables at baseline scan, but there was a trend for more male patients 
in the MRI-CT group (Table 2).
Imaging analysis – observer agreement
The intra-observer agreement in the MRI group was 0.82 and 0.51, for bronchiectasis and 
trapped air (sum score) respectively. In the CT group, intra-observer variability for bronchi-
ectasis 0.98 and for trapped air 0.68. 
MRI and CT correlations with clinical parameters (Table 3)
CF-MRI bronchiectasis correlated significantly with FEV1, Pseudomonas aeruginosa, pulmo-
nary exacerbations and patient-reported respiratory symptoms. CF-CT bronchiectasis was 
significantly, but less strongly correlated with FEV1, pulmonary exacerbations and patient-
reported respiratory symptoms. The correlation with Pseudomonas aeruginosa was weaker 
and did not reach significance (p=0.051).
MRI - CT CT - MRI p-values
Number of patients 23 34
Male gender (%) 15 (65.2) 14 (41.2) 0.08
Pulmonary exacerbation (%) 7 (30.4) 11 (32.4) 0.74
Pseudomonas aeruginosa (%) 16 (69.6) 26 (76.5) 0.57
Age at first scan, years 13.3 (6.6-16.5) 12.5 (5.6-17.4) 0.39
FEV1, % predicted 86.8 (30.3-111.5) 86.2 (39.8-110.1) 0.45 
FVC, % predicted 94.1 (53.9-119.2) 94.4 (56.9-119.4) 0.43
Respiratory symptoms on CFQ-R 83.0 (58-100) 76.5 (39-100) 0.42
Table 2. Comparison of baseline characteristics between children with MRI prior to CT compared with CT 
prior to MRI. 
Data are presented as n (%) or as median (range). A pulmonary exacerbation was present if treated with 
intravenous antibiotics in the year before baseline imaging. Pseudomonas aeruginosa, refers to the pres-
ence of Pseudomonas aeruginosa ever in a sputum culture before imaging was performed. 
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The CF-MRI trapped air sum score correlated significantly with FEV1 % predicted and Pseu-
domonas aeruginosa. CF-CT trapped air sum score was significantly correlated with FEV1 
and patient-reported respiratory symptoms, but not with Pseudomonas aeruginosa. Scatter 
plots showing those correlations are displayed in the on-line supplement. 
MRI and CT comparison for bronchiectasis 
and trapped air (Table 3, Figure 1,2)
CF-MRI bronchiectasis correlated with CF-CT bronchiectasis (r=0.67, p<0.001). The iden-
tity plot (Figure 1) shows that compared to CT, MRI tends to overestimate bronchiectasis 
across the whole range of disease severity. A lower correlation was found between CF-MRI 
and CF-CT trapped air scores (r=0.33, p=0.014, Figure 1). The ICC for CF-MRI bronchiec-
tasis and CF-CT bronchiectasis was 0.41 (95% confidence interval (CI95%) -0.09-0.71). Figure 
2 expresses the agreement between MRI and CT for bronchiectasis in a Bland-Altman plot; 
the average CF-MRI scores were 10 percentage points higher than CF-CT scores, but this 
difference appeared to increase as the average scores increase. 
FEV1 Pseudomonas
aeruginosa
Exacerbation Respiratory 
Symptoms
M
RI CF-MRI bronchiectasis score -0.59** 0.31* 0.45** -0.38**
CF-MRI trapped air sum score -0.52** 0.32* 0.24 -0.18
CT
CF-CT bronchiectasis score -0.38** 0.26 -0.36**
CF-CT trapped air sum score -0.34* 0.15* -0.34**
Table 3. Correlations between sub-scores for MRI and CT and clinical outcome measures.
A pulmonary exacerbation (in table called exacerbation) was present if treated with intravenous antibiot-
ics in the year before baseline imaging. Pseudomonas aeruginosa, refers to the presence of Pseudomo-
nas aeruginosa ever in a sputum culture before imaging was performed. Respiratory symptoms are the 
patient-reported	respiratory	symptoms	on	the	CFQ-R.	*significant,	p-value	<	0.05	(2-tailed).	**significant,	
p-value < 0.01 (2-tailed). 
Figure 1. Identity plots of CF-MRI vs. CF-CT bronchiectasis score (Figure 1.1) and CF-MRI vs. CF-CT 
trapped air sum score (Figure 1.2). Dashed line represents the line of identity (y=1*X).
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Weaker correlations were found between CF-MRI trapped air and CF-CT trapped air 
(r=0.33, p=0.014). For trapped air the ICC was 0.35 (CI95% 0.11-0.55). The Bland-Altman 
plot does not show a systematic difference (Figure 2). The limits of agreement are wide 
(-7.0 to +5.1) in comparison to the range of average trapped air sum scores.
 
DIsCUssIon 
To our knowledge this is the first study validating chest MRI as an imaging modality to de-
tect and monitor CF lung disease in the pediatric population by correlating bronchiectasis 
and trapped air scores with clinical parameters as FEV1, Pseudomonas aeruginosa, pulmo-
nary exacerbations and patient-reported respiratory symptoms. We also compared CF-MRI 
scores with CF-CT scores with respect to the detection of bronchiectasis and trapped air 
(12,18).
Our most important findings were the observed significant correlations between CF-MRI 
bronchiectasis scores and all investigated clinical parameters. It correlated well with FEV1 
% predicted, which is the most commonly used outcome parameter for CF-lung disease in 
clinical research. This finding is consistent with data from McMahon et al. who observed 
a similar correlation between bronchiectasis assessed by MRI and FEV1 in a small group 
of adults (24). Interestingly the observed association between CF-MRI bronchiectasis and 
FEV1 % predicted was stronger than the association between the CF-CT bronchiectasis 
and FEV1 % predicted. Significant correlations between CT bronchiectasis and FEV1 have 
been observed in several cross-sectional studies  (13,14,16). Since CT is considered to be 
a sensitive monitoring tool for CF lung disease and considering the observed associations, 
Figure 2. Bland-Altman plots of MRI versus CT for bronchiectasis and trapped air. The x-axis shows the 
average bronchiectasis (Figure 2.1) or the average trapped air score (Figure 2.2). The y-axis displays 
the differences between bronchiectasis scores on MRI and CT (Figure 2.1), or the differences between 
trapped air scores on MRI and CT (Figure 2.2). The middle line in both graphs is the mean and the two 
outer lines are the ±2SD.
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our results suggest that MRI could play a similar role in monitoring progression of bronchi-
ectasis. The next step is to compare the sensitivity of MRI to CT in tracking the progression 
of bronchiectasis over longer periods of time.
Our results report the first data on the associations between the CF-MRI bronchiectasis 
scores and other clinically relevant parameters, such as pulmonary exacerbations, Pseu-
domonas aeruginosa, and patient-reported respiratory symptoms. In contrast to CF-MRI 
bronchiectasis, no significant correlation was found between CF-CT bronchiectasis and 
Pseudomonas aeruginosa. This is consistent with the findings of Puderbach et al., who 
concluded that MRI is able to detect small pulmonary changes and that inflammation can 
be well characterized by MRI (11).  Thus, these findings suggest that MRI is able to detect 
inflammation before bronchiectatic changes appear on CT. Although the correlation be-
tween CT score and Pseudomonas aeruginosa was not statistically significant, the magni-
tude of the correlation was only slightly smaller than the correlation between the MRI score 
and Pseudomonas aeruginosa. 
Another new finding is the association between CF-MRI bronchiectasis and patient-report-
ed respiratory symptoms on the CFQ-R. A similar association was found between CF-CT 
bronchiectasis patient-reported respiratory symptoms, as previously reported by our group 
(16). Taking into account that the larger central bronchi are better visualized on MRI com-
pared to the smaller peripheral bronchi (18), this result suggests that these major bronchi-
ectatic changes have an important, negative effect on respiratory symptoms. We did not 
find a correlation between CF-MRI trapped air and patient-reported respiratory symptoms, 
while CF-CT trapped air was significantly associated with patient-reported respiratory 
symptoms, which is consistent with our previous study (16). A possible explanation for this 
might be that the pattern of trapped air can not yet be scored reliably on MRI (18). 
In our cross-sectional comparison of MRI and CT, we did not find any significant differ-
ences in baseline characteristics between the twenty-three patients who underwent the 
MRI a year before the CT and the 34 patients who underwent the CT a year before the 
MRI. Consistent with the results of Ciet et al, we found that MRI generally overestimates 
bronchiectasis compared with CT (18). Despite the use of the bSSFP sequence the spatial 
resolution of MRI was lower compared to the spatial resolution of CT, making the recogni-
tion of decreased attenuation of the pulmonary parenchyma (trapped air) more difficult. 
Other factors that could influence the image quality in the MRI are motion artifacts due to 
heart and vessel pulsation; by using the bSSFP sequence, we would expect less influence 
from motion artifacts (25).
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Implications
Our cross-sectional analysis showed that CF-MRI bronchiectasis was associated with clini-
cally relevant outcomes, some even stronger than CT, which is currently considered the 
gold standard for monitoring bronchiectasis and trapped air. MRI and CT assess bronchiec-
tasis and trapped air in a different way, as shown in the low correlations and ICCs between 
the two. This suggests that MRI may be able to detect other aspects of CF lung disease 
than CT. These findings support of our current strategy of alternating MRI and CT in follow-
ing our CF patients. 
Limitations
An important limitation in this comparison of MRI with CT is the fact that these scans were 
not performed on the same day, but were separated by a median interval of one year. In 
theory, differences between MRI and CT may therefore be explained by disease progres-
sion rather than differences in sensitivity and specificity of the MRI. However it is unlikely 
that this is the case. First, the order in which the MRI and CT were performed was random 
and on average, there was no difference between the patients’ age at time of MRI and CT. 
Second, on average not much disease progression is expected over a one-year period (13). 
Furthermore, bronchiectasis is a stable and irreversible condition. Finally, we found bron-
chiectasis to be overestimated on MRI compared to CT, irrespective of the order of the two 
scans. Therefore, it is unlikely that our results can be explained by the time lag between 
the two scans. 
The fact that we used data collected from a single center reduces the generalizability of our 
results. In addition, chest MRI protocols are poorly standardized between centers and the 
protocol, selected, may greatly influence the sensitivity of MRI to detect changes related 
to CF lung disease. A multi-sequence protocol might further improve MRI sensitivity (26). 
Although the CF-MRI scoring system has been used in a previous study, the CF-MRI scor-
ing system was adapted from the CF-CT scoring method and not specifically designed for 
MRI. A more sophisticated scoring method could improve the sensitivity of the MRI  (11,18).
Further, the fact that we included patients who ranged from 6 to 20 years, with relatively 
mild CF disease, limits the generalizability of our findings to this younger age group and 
those with less severe disease. Finally, because the MRIs were scored by a different ob-
server than the CTs, we cannot exclude the possibility that this may have introduced a 
systematic difference between the two imaging modalities. However, it is unlikely that this 
affects the general conclusion of our study since the observers were experienced and well 
trained in scoring MRIs and CTs. Furthermore the intra-observer variability in both MRI and 
CT were good. 
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Conclusion
The observed associations between MRI and clinical parameters further validates chest MRI 
as a method to monitor CF lung disease. Our results suggest that the MRI provides differ-
ent information than CT. Next, longitudinal studies are needed to compare the sensitivity 
of CT and MRI to track disease progression.
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MRI and CT acquisition
All MRI scans were performed using a 1.5T unit (Excite HD, software release 12, General 
Electric Healthcare, Milwaukee, WI). The body coil provided radiofrequency excitation. An 
eight-channel phased-array receive cardiac coil was used for larger, more compliant sub-
jects, a four channels smaller flexible one for smaller subjects. The system had a gradient 
hardware capable of a maximum gradient strength of 40 mT/m with a rise time of 266 s 
to maximum. The scan protocol started with two three-plane orthogonal localizers col-
lected first in expiration and next in inspiration (4 s). For the inspiratory localizer, shim-
ming was performed and the resulting images served as base localizers for all subsequent 
scans. These shim settings were maintained throughout scanning. Instructions for voluntary 
breath holds were given before scanning. Six breath-hold scans of maximum 10 s were 
done in all orthogonal planes (axial, coronal, and sagittal), covering the whole lung region, 
in full inspiration and end-expiration using an ultra-short TR/TE 2D SSFP with TR/TE = 
2.2/0.7 ms and flip angle 35°. The flip angle was chosen upon testing on healthy volun-
teers to obtain adequate signal from lung parenchyma and, subjectively, a good intensity 
balance between blood and fat signals. The in-plane resolution was kept constant with a 
field-of-view of 360 mm using a scan matrix 128 x 180 (frequency/phase-encodings) result-
ing in 2.8 x 2.0 mm2 in-plane resolution and a section thickness of 8 mm and no gap. To 
evaluate the airways and permit comparison with CT, scans were performed in inspiration 
using 6-mm slices with no gap and 2.3 x 1.4 mm2 in-plane resolution with TR/TE/flip angle 
= 2.6/0.9/20°. All sequences used are generally available in the imaging protocols on the 
GE system. The scan was divided in two 10-s breath-holds to cover the entire chest. The 
complete MRI scan time lasted no more than 15 min(1). 
All volumetric CTs were acquired using a 6-slice multi-detector CT scanner (Somaton Emo-
tion, Siemens Medical Solutions, Erlangen, Germany). Each chest-CT consisted of a volu-
metric inspiratory and expiratory acquisition. Instructions for voluntary breath holds were 
given before scanning or the CT was spirometry controlled. kV tube voltages of 80 (patients 
< 35 kg) to 110 (patients > 35 kg) were used with a 0.6-sec rotation time. Scanning was 
done from apex to base at 1.5 pitch and 6x2 mm collimation. Images were reconstructed 
with a 3.0 mm slice thickness, 1.2 mm increment and kernel B60s. For the inspiratory pro-
tocol a modulating current was used (CareDose4D, Siemens Medical Solutions) with a ref-
erence tube current-time product of 20 mAs, for an optimal image quality. For expiratory 
CTs, image quality was considered sufficient using a tube current fixed at 25 mA with an 
effective tube current-time product of 10 mAs; producing a lower radiation dose than the 
inspiratory protocol. Total radiation dose was in the order of 1 mSv.
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MRI and CT correlations with clinical parameters (Figures 1-4)
The significant associations between MRI and CT assessments of bronchiectasis and 
trapped air scores and FEV1 % predicted (%pred) are shown in Figure 1.1-1.4.
CF-MRI (Figure 2.1), CF-CT bronchiectasis score (Figure 2.2) CF-MRI trapped air scores (Figu-
re 2.3) were significantly associated with Pseudomonas aeruginosa, whereas no association 
was found between the CF-CT trapped air score and Pseudomonas aeruginosa (Figure 2.4). 
There was a significant association between CF-MRI bronchiectasis (Figure 3.1), CF-CT 
bronchiectasis (Figure 3.2) and pulmonary exacerbations in the year prior to MRI or CT. No 
association was found for CF-MRI trapped air (Figure 3.3) or CF-CT trapped air (Figure 3.4) 
and pulmonary exacerbations in the year prior to MRI or CT. 
e-Figure 1.4 The	significant	association	between	
CF-CT trapped air scores and FEV1 % predicted 
(%pred).
e-Figure 1.1 The	significant	association	between	
CF-MRI bronchiectasis scores and FEV1 %  
predicted (%pred). 
e-Figure 1.2 The	significant	association	between	
CF-CT bronchiectasis scores and FEV1 % predicted 
(%pred). 
e-Figure 1.3 The	significant	association	between	
CF-MRI trapped air scores and FEV1 % predicted 
(%pred).
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There was a significant association between CF-MRI bronchiectasis (Figure 4.1),  CF-CT 
bronchiectasis (Figure 4.2) and patient-reported respiratory symptoms measured with the 
Cystic Fibrosis Questionnaire-Revised. No associations were found for CF-MRI trapped air 
(Figure 4.3), CF-CT trapped air (Figure 4.4) and patient-reported respiratory symptoms 
measured with the Cystic Fibrosis Questionnaire-Revised.
e-Figure 2.1 The	significant	association	between	
CF-MRI bronchiectasis and Pseudomonas aerugi-
nosa.
e-Figure 2.2 The	significant	association	between	
CF-CT bronchiectasis and Pseudomonas aerugi-
nosa.
e-Figure 2.3 The	significant	association	between	
CF-MRI trapped air scores and Pseudomonas aeru-
ginosa.
e-Figure 2.4 The association between CF-CT 
trapped air scores and Pseudomonas aeruginosa.
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e-Figure 3.1 The	significant	association	between	
CF-MRI bronchiectasis and pulmonary exacerba-
tions in the year prior to MRI. 
e-Figure 3.2 The	significant	association	between	
CF-CT bronchiectasis and pulmonary exacerbations 
in the year prior to CT. 
e-Figure 3.3 The association between CF-MRI 
trapped air scores and pulmonary exacerbations in 
the year prior to MRI.
e-Figure 3.4 The association between CF-CT 
trapped air scores and pulmonary exacerbations in 
the year prior to CT.
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e-Figure 4.4 The associations between CF-CT 
trapped air scores and patient-reported respira-
tory symptoms measured with the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R).
e-Figure 4.1 The	significant	association	between	
CF-MRI bronchiectasis and patient-reported  
respiratory symptoms measured with the Cystic 
Fibrosis Questionnaire-Revised (CFQ-R). 
e-Figure 4.2 The	significant	association	between	
CF-CT bronchiectasis and patient-reported respira-
tory symptoms measured with the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R).
e-Figure 4.3 The association between CF-MRI 
trapped air scores and patient-reported respira-
tory symptoms measured with the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R).

Chapter 7
Discussion
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In this thesis, we aimed to further validate chest CT, chest MRI and the CFQ-R as outcome 
measures for clinical management and clinical trials in CF lung disease. In this chapter we 
discuss the main findings of our studies in the context of current literature, their implica-
tions and directions for further research.
The first important finding in the validation of chest CT is that more severe bronchiecta-
sis was significantly associated with worsening of respiratory symptoms as measured by 
the Cystic Fibrosis Questionnaire-Revised Respiratory Symptoms scale (CFQ-R RSS). In the 
studies described in chapter 2 and 3, we showed that in a cohort of children with CF, more 
severe bronchiectasis and trapped air are associated with worse quality of life scores, as 
measured by the CFQ-R RSS. Although, the importance of bronchiectasis in CF lung dis-
ease has been well established (1-7), the impact of bronchiectasis on patient-reported 
outcome measures in CF had not been examined (8). Our finding that bronchiectasis and 
CFQ-R RSS are negatively associated further supports the validity of bronchiectasis as a 
clinically relevant outcome measure.
Trapped air has been less well validated as an outcome measure. We found a significant 
correlation between trapped air and CFQ-R RSS, independent of the presence of bron-
chiectasis. Although the association between CF-CT trapped air scores and CFQ-R RSS 
was significant, it was not as strong as the associations with bronchiectasis. This suggests 
that trapped air has less impact on patient functioning than bronchiectasis. This can be 
explained by previous studies showing that trapped air in contrast to bronchiectasis is 
reversible to some extent (4,5,9). Furthermore, a recent study showed that the patients 
with severe advanced lung disease and a high volume fraction of bronchiectasis, had a 
higher mortality risk compared to patients who predominantly had a high volume fraction 
of trapped air (5). Our results add further support to the importance of trapped air as a 
clinical relevant outcome measure for CF lung disease. 
The second important group of findings of this thesis is the significant associations between 
CF-CT airway wall thickening, mucus plugging, opacities and the CFQ-R RSS in children 
and adolescents. Airway wall thickening and mucus plugging are considered to be early 
indicators of progressive CF lung disease, which are thought to lead to the development of 
bronchiectasis (4,5). These early indicators were also significantly associated with the CFQ-
R RSS in the younger age group. These findings further validate both CT and the CFQ-R 
RSS as sensitive measures of structural lung damage in the early stages of CF lung disease. 
Additionally, this supports the view that airway wall thickening and mucus plugging could 
be used as outcome measure in clinical trials focused on the treatment of CF lung disease. 
The third important group of findings presented in chapter 6 are the observed significant 
cross sectional correlations between bronchiectasis and trapped air scores detected by 
chest MRI and clinical parameters, FEV1 % predicted, Pseudomonas aeruginosa infection, 
pulmonary exacerbations and patient reported outcomes. Some of these correlations for 
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MRI are even stronger than for CT, which is considered the gold standard for monitoring 
bronchiectasis and trapped air (10). This is the first study assessing these correlations and 
therefor contributes importantly to the validation of chest MRI related outcome measures 
as an imaging modality to detect and monitor CF lung disease in children and adolescents 
with CF. MRI and CT assess bronchiectasis and trapped air in a different way (11), as shown 
by the poor correlations and interclass correlation coefficients between the two, suggest-
ing that MRI detects other aspects of CF lung disease than CT. These findings support our 
current clinical practice of alternating biennial MRI and CT in monitoring our CF patients. In 
addition it supports the importance of further validating MRI as a radiation free alternative 
in monitoring CF lung disease.
The fourth important finding was that a low quality of life as indicated by a low CFQ-R RSS 
score is associated with a higher risk for future pulmonary exacerbations, irrespective of 
other predictors. This novel finding shown in chapter 2, is in-line with what we would ex-
pect based on the results of the study performed by Britto et al. (12). They concluded that 
pulmonary exacerbations have a profound, negative impact on health-related quality of life 
in CF-children, using a generic instrument (Child Health Questionnaire). Furthermore, our 
data suggested that the CFQ-R RSS is sensitive to detect early, minor respiratory symptoms 
that are preceding pulmonary exacerbations. This stresses the importance of the CFQ-R 
RSS as a tool to systematically evaluate symptoms.
The fifth important finding was that two thirds of bronchiectases on CT did not reveal early 
structural changes in the CT made two years prior to the first occurance. In chapter 5, we 
describe the first longitudinal study to identify pre-stages of bronchiectasis in children with 
CF. In 17.7% of the newly developed bronchiectasis we identified mucous plugging as a 
pre-stage of bronchiectasis. This suggest that the presence of mucus plugging should be 
taken seriously as it could lead to irreversible bronchiectasis. Due to radiation exposure, 
it is not advisable to repeat CT-scanning within short time intervals. Therefore we have to 
identify other sensitive non-invasive outcome measures to detect mucus plugging. Fur-
thermore our study confirmed that in the majority of cases, CT diagnosed bronchiectasis 
was persistent and therefore irreversible, which is consistent with the results of a study per-
formed in young children up to the age of 6.5 years (4). This study together with our study 
highlights the importance to prevent the development of bronchiectasis.
The sixth important finding was that the strongest predictor for bronchiectasis in teenage 
years was the presence of bronchiectasis at a CT made 6 year earlier (CT1). Predictors of 
bronchiectasis at that first CT were FEV1, a pulmonary exacerbation in the year prior to the 
CT and Pseudomonas aeruginosa infection ever. CF-CT bronchiectasis score at CT1 could 
predict only 0.03% of the increase in bronchiectasis during the 6-year follow-up, and none 
of the other tested variables could add any predictive value in the multivariate model. 
Another striking observation from this study was that in contrast to a previous cohort study 
performed by our group, the annual increase in the CF-CT bronchiectasis score decreased 
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from 1.7% to only 0.4% in our current cohort (13). The real difference might even be bigger 
since we used in our recent study a more sensitive CT protocol than used in the previous 
study. Many improvements in the monitoring strategy and treatment of CF lung disease 
can have contributed to this result, with routine biennials use of chest CT to direct therapy 
being one of them. 
In addition to bronchiectasis we also investigated risk factors for the development of 
trapped air. The most important risk factors that were identified were bronchiectasis and 
trapped air. Using backward stepwise multivariate analyse, the female gender remained the 
strongest predictor of trapped air severity 6 years later. Previous studies have also reported 
a gender difference in clinical outcomes  (14,15), which may be explained by the role of 
sex hormones (15). It is an interesting finding that requires further investigation in a larger 
cohort. 
Clinical implications
The results of our studies presented in this thesis, in addition to previous studies confirm 
the role that CT, MRI and CFQ-R all can play in the follow up of CF lung disease, but they all 
have different advantages, provide different information and have different recall windows. 
To monitor CF lung disease and to assess the effect on a patient’s daily life multiple modali-
ties are needed. Our studies showed that the variability in bronchiectasis and trapped air 
on chest CT was lower than the variability in CFQ-R RS, implying that CT was more sensitive 
than CFQ-R RSS at detecting a change in structural lung disease. However, the CFQ-R sup-
plies us with insight into how CF lung disease impacts the lives of CF patients
We added a validation study to the portfolio of chest MRI as a radiation free monitoring 
modality for CF lung disease. Relative to chest CT many more studies are needed to further 
establish the role of chest MRI to monitor CF lung disease. MRI using today’s technology 
is less sensitive to monitor bronchiectasis and trapped air especially in early disease. How-
ever, MRI can potentially be used in the future to evaluate the dynamic consequences of CF 
lung disease and to study lung perfusion in more detail. Our findings support our current 
strategy of alternating MRI and CT in following our CF patients to guide our therapy. 
Although we showed that the annual increase in the CF-CT bronchiectasis score decreased 
from 1.7% to only 0.4%, we unfortunately have not succeeded yet in preventing the devel-
opment of bronchiectasis. Importantly, studies in young CF patients are ongoing to prevent 
the development of bronchiectasis. 
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Future directions
General
The studies in this thesis added important information further validating chest imaging as 
an outcome measure for CF lung disease. Clinical studies have been initiated using chest 
CT as a primary outcome measure to monitor and assess the efficacy of various treatments. 
The use of chest CT as a more sensitive outcome measure for CF lung disease compared to 
the previously used functional outcome measures has important advantages. Such studies 
will require a smaller sample size to establish the effect of medications for CF lung disease. 
Chest CT could especially add important information for clinical studies evaluating the ef-
ficacy of recently developed expensive CFTR correctors and potentiators. 
Image quality control and radiation
To allow clinical multi centre studies that include chest CT great effort should be put into 
worldwide standardization of CT protocols. Care should be taken to optimize image quality 
at the lowest possible radiation dose. 
To further optimize image quality it is important to optimize volume control. This is of 
key importance for the assessment of bronchiectasis and trapped air (16,17). In addition, 
great effort should be directed to standardize and improve sensitivity of CT image analysis. 
Automated image analysis systems to quantify bronchiectasis and trapped air have great 
potential to replace time consuming scoring systems.
In order to reduce radiation exposure stratified personalized monitoring should be de-
veloped. Currently, monitoring protocols do not distinguish between high and low risk 
patients.
MRI and multimodality monitoring
Clearly, the use of MRI for monitoring CF lung disease is interesting. However, to intro-
duce chest MRI on a wider scale standardization of protocols and validation of MRI related 
outcome measures is needed. Efforts should be directed towards further optimization of 
imaging quality of chest MRI. It is questionable whether morphological chest MRI proto-
cols will ever be of sufficient quality to compete with the chest CT.  More promising is the 
ability of chest MRI to study the consequences of CF lung disease on lung perfusion and 
ventilation. However, any newly developed MRI functional outcome measure will require 
an adequate validation program comparable to what has been done for chest related out-
come measures. 
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Finally, our studies evaluated various modalities for monitoring CF lung disease each with 
their unique advantages and disadvantages. Therefore, future research should also focus 
on strategies for multi-modality monitoring.  
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Chapter 1 contains a general introduction to cystic fibrosis (CF) and formulates the aims of 
the studies presented in this thesis.
In the first part of this thesis we present the studies that aimed to assess the impact of CF 
on health related quality of life. The impact of CF lung disease is primarily determined by 
the development of bronchiectasis and trapped air (1). Studies showed that bronchiectasis 
are associated with pulmonary exacerbations (2,3), are an indicator of end-stage lung dis-
ease (1), and are associated with mortality (1). Compared to bronchiectasis, trapped air has 
been less well investigated. To date, trapped air has not yet been associated with clinical 
markers of disease severity, such as pulmonary exacerbations and patient-reported respira-
tory symptoms on a health-related quality of life measure. A well-validated health-related 
quality of life measure is the Cystic Fibrosis Questionnaire-Revised Respiratory Symptoms 
scale (CFQ-R RSS) (4-12). Although a minimal important difference has been established 
for the CFQ-R RSS, it is not clear what change in respiratory symptoms reflects the extent 
of bronchiectasis and trapped air (13). The extent of bronchiectasis and trapped air can be 
assessed by chest CT (1,14-18). Therefore we investigated in Chapter 2 whether CT scores 
for bronchiectasis and trapped air were correlated with quality of life scores (CFQ-R RSS) 
and what their predictive value for pulmonary exacerbations in the following year was. We 
included 40 children and 32 adolescents. Our most important finding was that bronchi-
ectasis; trapped air and CFQ-R RSS were all significantly associated with each other and 
with pulmonary exacerbations in the following year. However, the CFQ-R RSS was the only 
independent predictor for pulmonary exacerbations in the following year. These results 
suggest that especially pulmonary exacerbations have a profound, negative impact on 
health-related quality of life in CF-children. 
Additionally we describe in Chapter 3 the longitudinal associations between changes in 
bronchiectasis, trapped air, and patient-reported respiratory symptoms over a two years 
time period. In total 40 patients were included with a median age at T1 of 12.6 years (range 
6-17 years), and at T2 14.5 years (range 8-19 years). Over two years, there was a significant 
progression in bronchiectasis (p=0.03) and trapped air (p=0.03). However, the progression 
of bronchiectasis and trapped air over two year did not correlate to changes in quality of 
life. 
In part two of this thesis we describe two studies further contributing to the validation pro-
cess of chest CT as an outcome measure. Chapter 4 describes the first longitudinal study 
to identify predictors of subsequent bronchiectasis and trapped air severity in a cohort of 
children over 6 years of age. Twenty-three children with a median age of 9.4 years (range 
7-13 years) with a follow up of 6 years were included. We showed that the bronchiectasis 
score at CT1, FEV1 % predicted at CT1 and Pseudomonas aeruginosa infections before CT1 
were predictive of bronchiectasis severity at CT2. However, the effect of the latter two ap-
peared to be mediated through bronchiectasis at CT1, which was the only independent 
predictor for bronchiectasis severity 6 years later in a multivariate model. The identified 
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predictors for trapped air severity at CT2 were the bronchiectasis score at CT1, a pulmonary 
exacerbation in the year prior to CT1, and female gender. However, in backward step-
wise multivariate analyses only the female gender remained as the strongest predictor of 
trapped air severity 6 years later. 
An important step in the validation process of chest CT was to identify pre-stages of bron-
chiectasis in CF on chest CT and to determine which patients are at risk for a rapid pro-
gression of bronchiectasis. Our observations described in Chapter 5 provide unique in-
sight into the radiologic course of developing bronchiectasis. Our most important findings 
were that bronchiectasis appeared mostly within the 2-year timeframe between successive 
scans. Of the pre-stages that could be identified, mucus plugging was the most common 
predecessor of bronchiectasis. Development of bronchiectasis without clearly identifiable 
pre-stages of bronchiectasis was commonly seen in this study, suggesting that the devel-
opment of most bronchiectasis is an acute process are not caused by a slow continuous 
progressive process visible on chest CT. This study illustrates the treacherous nature of CF 
lung disease and highlights the importance of more accurate and sensitive monitoring op-
tions in order to prevent the development of structural lung damage.
In part three of this thesis we describe the study that contributed to the validation of chest 
MRI as an outcome measure. However, for chest MRI, in contrast to chest CT, the validation 
process is at an early stage. Only few studies have validated MRI derived outcome mea-
sures for CF lung disease (19-21). In Chapter 6 we describe the first study that validated 
MRI against established outcome measures of CF lung disease such as FEV1, Pseudomonas 
aeruginosa infection, pulmonary exacerbations and quality of life, measured with the CFQ-
R. We included fifty-seven patients (5.6-17.4 years). Our most important findings were the 
observed significant correlations between CF-MRI bronchiectasis scores and all investi-
gated clinical parameters. Furthermore CF-MRI trapped air scores correlated with FEV1 and 
Pseudomonas aeruginosa infection. The associations between CF-MRI scores and clinical 
parameters contribute to the validation of chest MRI in CF. When comparing the correla-
tions of this MRI study with those of CT studies, less strong correlations are observed, sug-
gesting that MRI provides different information than CT. The MRI could play an additional 
role in monitoring progression of CF lung disease. 
Finally, Chapter 7 provides the discussion of the main findings of the studies presented in 
this thesis, the clinical implications and suggestions for future research.
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Hoofdstuk 1 is een introductie met achtergrond informatie over de ziekte cystic fibrosis 
(CF), de opbouw van dit proefschrift en beschrijft de doelstellingen van de studies die in 
dit proefschrift worden besproken.
In het eerste deel van dit proefschrift beschrijf ik de impact van CF op de kwaliteit van 
leven. De ernst van CF wordt voornamelijk bepaald door de ernst van de longziekte. CF 
longziekte wordt gekenmerkt door onherstelbare afwijkingen van de kleine luchtwegen, 
genaamd trapped air en in de grote luchtwegen, genaamd bronchiectasiën. Met longscans 
(CT) kan deze longschade aan kleine en grote luchtwegen worden opgespoord en worden 
vervolgd 
Verschillende onderzoeken in CF hebben aangetoond dat er een relatie bestaat tussen 
bronchiectasiën en een plotselinge verergering van de longklachten (pulmonale exacerba-
ties) (2,3),  dat bronchiectasiën een belangrijke onderdeel zijn van eindstadium longziekte 
(1) en dat er een relatie bestaat tussen bronchiectasiën en  de kans op vroegtijdig overlij-
den (1). In vergelijking met bronchiectasiën zijn er minder studies gedaan naar de klinische 
betekenis van trapped air. Zo waren er geen onderzoeken gedaan naar de samenhang 
tussen trapped air en relevante patiëntkenmerken zoals een plotselinge verergering van de 
longklachten (pulmonale exacerbaties) en kwaliteit van leven. Kwaliteit van leven is te me-
ten met een gevalideerde vragenlijst, genaamd de Cystic Fibrosis Questionnaire-Revised 
Respiratory Symptoms scale (CFQ-R RSS) (4-12). Van deze vragenlijst is bekend welke ver-
mindering in score een verslechtering van kwaliteit van leven betekend. Nog niet bekend 
is of het ontstaan van bronchiectasiën en trapped air een vermindering in score tot gevolg 
heeft (13). De ernst van bronchiectasiën en trapped air kan met behulp van scoringsmetho-
des op een longscan worden gemeten (1,14-18). In hoofdstuk 2 onderzoeken we in hoe-
verre er een samenhang is tussen deze van de longscan afgeleide scores voor bronchiec-
tasiën en trapped air en kwaliteit van leven zoals gemeten met de CFQ-R RSS vragenlijst. 
Ook wordt onderzocht of en in hoeverre deze scores een plotselinge verslechtering van de 
longklachten in het jaar na de longscan (CT) kunnen voorspellen. Aan dit onderzoek deden 
72 kinderen mee.  Ons belangrijkste resultaat was dat er een samenhang bestaat tussen: 
het aantal bronchiectasiën, de hoeveelheid trapped air en kwaliteit van leven scores geme-
ten met de CFQ-R RSS vragenlijst en het voorkomen van een plotselinge verergering van 
de longklachten (pulmonale exacerbaties). De kwaliteit van leven scores gemeten met de 
CFQ-R RSS vragenlijst konden de kans dat er een jaar later een plotselinge verergering van 
de longklachten optreedt voorspellen. 
In hoofdstuk 3 beschrijven we de samenhang tussen een toename van bronchiectasiën en 
trapped air over een periode van 2 jaar en de kwaliteit van leven vragenlijst scores (CFQ-
R RSS). We hebben in 40 patiënten met een gemiddelde leeftijd op het moment van de 
eerste longscan (T1) van 12.6 jaar en bij de tweede longscan (T2) van 14.5 jaar gekeken of 
er een toename was van het aantal bronchiectasiën en de hoeveelheid trapped air over 
een periode van 2 jaar en wat daarbij de kwaliteit van leven vragenlijst scores waren. Gedu-
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rende de studieperiode van 2 jaar zagen we een duidelijke toename in bronchiectasiën en 
van trapped air. Deze toename van bronchiectasiën en trapped air hing echter niet samen 
met een verslechtering in de kwaliteit van leven scores. 
Toename in bronchiectasiën en trapped air resulteert uiteindelijk bij  90% van de CF patiën-
ten in vroegtijdig overlijden. Daarom is het voorkomen bronchiectasiën en trapped air een 
belangrijk behandelingsdoel. Om dit te voorkomen is het belangrijk dat vroege voorspel-
lers voor bronchiectasiën en trapped air worden ontdekt zodat er tijdig behandeling kan 
worden ingesteld en onomkeerbare longschade kan worden voorkomen. Hoewel er veel 
onderzoek is verricht met longscans (CT), was er nog geen onderzoek gedaan naar voor-
spellers voor het optreden van longschade als bronchiectasiën en trapped air in kinderen 
ouder dan 6 jaar en naar het identificeren van vroege stadia of voorstadia van bronchiecta-
siën op CT. Deel 2 van dit proefschrift beschrijft een tweetal studies waar we dit onderzocht 
hebben. Hoofdstuk 4 is de eerste studie in kinderen ouder dan 6 jaar waarin voorspellers 
voor de ernst van bronchiectasiën en trapped air worden geïdentificeerd. Voor deze studie 
werden 23 kinderen met een gemiddelde leeftijd van 9.4 jaar en met een follow-up van 
6 jaar bestudeerd. Op de eerste CT (CT1) die gemaakt werd rond de leeftijd van 7-13 
jaar werd gekeken wat de hoeveelheid bronchiectasiën was. Daarbij werd gekeken wat de 
longfunctie ten tijde van die longscan was, of de kinderen een plotselinge toename van de 
longklachten hebben gehad, of dat de kinderen een ernstige longinfectie met de Pseudo-
monas aeruginosa bacterie doorgemaakt hadden en of er geslachtsverschillen waren in het 
krijgen van bronchiectasiën en trapped air. Vervolgens werd gekeken of deze factoren de 
ernst van bronchiectasiën en trapped air 6 jaar later konden voorspellen. Bronchiectasiën 
op CT1 bleek de belangrijkste onafhankelijke voorspeller te zijn voor de mate van bron-
chiectasiën 6 jaar later. De score voor bronchiectasiën op de eerste longscan, het hebben 
doorgemaakt van een ernstige longinfectie in het jaar voorafgaand aan de eerste longscan 
en het vrouwelijke geslacht konden de uitgebreidheid van trapped air op de longscan die 
6 jaar gemaakt was voorspellen. 
Hoofdstuk 5 beschrijft een studie die een uniek inzicht in de ontwikkeling van bronchiec-
tasiën op een longscan geeft. Het beschrijft de studie waarin we voorstadia van bronchiec-
tasiën op een longscan hebben bestudeerd. Tevens hebben we geprobeerd te bepalen 
welke patiënten een snelle toename van bronchiectasiën lieten zien. Onze belangrijkste 
bevinding was dat de meeste bronchiectasiën zich binnen een periode van 2 jaar ontwik-
kelden. Het enige voorstadium dat kon worden geïdentificeerd waren slijmpluggen. Voor 
de meeste bronchiectasiën kon met CT geen voorstadium worden geïdentificeerd. Dit kan 
betekenen dat de ontwikkeling van bronchiectasiën een snel optredend proces is of dat er 
nieuwe en meer gevoelige scans nodig zijn om meer subtiele voorstadia van bronchiecta-
siën tijdig op te sporen.
In het derde deel van dit proefschrift beschrijven we een studie waarin we onderzoeken of 
MRI een goede methode is om bronchiectasiën en trapped air op te sporen.  Dit wordt va-
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lidatie genoemd. Het validatieproces van de MRI als uitkomstmaat bevindt zich nog in een 
vroege fase (19-21). In hoofdstuk 6 presenteren we de eerste studie die de samenhang 
onderzoekt tussen MRI scores voor bronchiectasiën en trapped air en longfunctie, het heb-
ben doorgemaakt van een Pseudomonas aeruginosa infectie, een pulmonale exacerbatie 
en kwaliteit van leven. Voor dit onderzoek werden 57 patiënten onderzocht. Onze belang-
rijkste bevinding was de samenhang tussen bronchiectasiën en alle onderzochte markers. 
De ernst van trapped air hing samen met de longfunctie en het hebben doorgemaakt 
van een Pseudomonas aeruginosa infectie. Als we deze MRI resultaten vergelijken met 
soortgelijke studies voor CT dan zien we dat de samenhang voor MRI minder overtuigend 
is dan CT. Dit suggereert dat MRI een minder gevoelige techniek is om een toename van 
bronchiectasiën en trapped air te meten. Verder suggereert dit resultaat dat de MRI andere 
informatie weergeeft dan de CT. Het blijft dus mogelijk dat de MRI van aanvullende waarde 
kan hebben voor het monitoren van CF longziekte.
Tot slot bevat hoofdstuk 7 een discussie van de belangrijkste bevindingen van de studies 
die gepresenteerd worden in dit proefschrift, de klinische consequenties van de resultaten 
en suggesties voor verder onderzoek.
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- Course NIH grant writing, Erasmus MC
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2010
2011
2011
2011
2010
2011
2012 
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4.0
1.0
1.9
1.4
0.2
0.2
2.0
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- ERS School Course “CF basic course” 2010 0.9
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- Symposium Nederlands Cysitic Fibrosis stichting 
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- Symposium Nederlands Cysitic Fibrosis stichting 
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- CF centrale (oral presentation)
- 5e Jonge onderzoekersdag NVK: Onderhandelen en 
presentatietechnieken
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2011
2012
2011
2011
0.2
0.3
0.3
0.2
0.3
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- 25th North American Cystic Fibrosis Conference, Anaheim, 
UAS (poster presentation)
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(poster presentation)
- 35th European Cystic Fibrosis Conference, Dublin, Ireland
(poster presentation)
- 26th North American Cystic Fibrosis Conference, Orlando, 
USA
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- 27th North American Cystic Fibrosis Conference, Salt Lake 
City, USA
(poster presentation)
2010
2011
2011
2012 
2012 
2013
1
1
0.3
0.3
1
1
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- Instructor CT scoring 2010-2014 1
2. Teaching
Supervising practicals and excursions, Tutoring
- Asthma and inhalation medication (1th year medical students) 2011 0.3
Supervising Master’s theses
- A.C. Bos: “Effect of air trapping on quality of life in cystic 
fibrosis	lung	disease.”
2011 0.3
Other
- Outpatient clinic pediatric pulmonology
- Writing club 
- Researchmeeting (every Friday)
- Quality of life PhD meeting (monthly)
-	 Peer	review	for	articles	for	scientific	journals
2010-2014
2012-2013
2010-2014
2012-2014
2011
6
3
3
1
1.5
Total 34.1
